# Literature Review

## CHAPTER 1

### 1. 1 Overview of HIV/AIDS

Human Immunodeficiency Virus (HIV) is a human pathogenic virus that cause AIDS (Acquired Immunodeficiency Syndrome). HIV/AIDS has been global pandemic for over the last three decades and is depicted as the modern day plague (Quinn, 1996). The United Nations Acquired Immune Deficiency Syndrome (UNAIDS) global report 2012 estimates that by the end of 2011 approximately 34 million people were living with HIV by the end of 2011 (WHO factsheet Number 360 (<http://www.who.int/mediacentre/factsheets/fs360/en/>)) and that over 95% of them are living in low and middle in come countries (Esparza and Bhamarapravati, 2000). There is a significant variation in HIV prevalence among the countries around the globe (Figure 1.1). The UNAIDS 2012 report shows that although the global trend of new HIV infections and HIV-related deaths per year is declining, the current number of HIV infections is the highest since 1990 (Figure 1.2). The sub-Saharan region of Africa is the region most aggravated by the virus with 23.5 million people living with HIV (UNAIDS). UNAIDS estimates that approximately 1 in every 20 adults is HIV infected in this region (UNAIDS). This is 25 or more times the HIV prevalence in any other region of the world. Countries in Sub-Saharan Africa also have varying HIV prevalence with South Africa at the top followed by Nigeria (Esparza and Bhamarapravati). The next severely affected regions, besides African continent, are Asia (China, Thailand, Indonesia), Caribbean and Eastern Europe, North America, western and central Europe (Esparza and Bhamarapravati).




Figure 1.1: Distribution of HIV prevalence in adults around the world.

Source: http://www.unadis.org/en/dataanalysis/datatools/aidsinfo/

hiv global trend.pdf

Figure 1.2: Global trend of new HIV infections from 1990 to 2011. The number of people living with HIV globally is increasing (A) while the number of people newly infected with HIV (B) and the number of Adults and child deaths due to HIV are decreasing (C) globally in the time period. This scenario can be attributed to global scale up of drugs while infected people continue transmitting the virus to uninfected people (Zaidi et al.). (Source: modified from UNAIDS 2012)

### 1.2 Discovery and characterization of HIV

As early as 1959, HIV infection cases had been documented but were unreported (Corbitt et al., 1990; Nahmias et al., 1986). Curious doctors at that time collected patient blood samples and kept frozen, which were later shown to have HIV antibodies (Zhu et al., 1998). In June 1981, a case of acute immune depletion associated secondary infection was reported in some homosexuals in the USA (Friedman-Kien, 1981; Friedman-Kien et al., 1981). Their infection was coupled with no lymphocyte proliferation (Gottlieb et al., 1981). Until 1983, the causative agent responsible for the severe immune depletion, named AIDS (Acquired Immunodeficiency Syndrome), was unknown (Francis et al., 1983; Gallo et al., 1983), when Luc Montagnier’s group at “Institut Pasteur” in Paris isolated the virus, which was initially named Human T-cell Leucamia Virus (HTLC) and later named as Human Immunodeficiency Virus (HIV) (Nahmias et al., 1986). Jay Levy’s group in San Francisco, USA also subsequently found the virus confirming the discovery in Paris (Levy et al., 1984). They found HIV was a lentivirus from Group VI retrovirus with two single strand RNA molecules (Baltimore, 1971); unique to any other previously isolated viruses and the virus can transmit from infected to healthy people (Rogers et al., 1987; Wofsy et al., 1986), mother to child through umbilical cord (Gallo et al., 1983; Ziegler et al., 1985).

Very soon, scientists around the world focused on this transmissible retrovirus. Complete sequencing of HIV genome in 1985 (Ratner et al., 1985) led scientists to know more insights of HIV including its origin, genes/proteins and life cycle (Wain-Hobson et al., 1985).

## 1.3 Origin and evolution of HIV

Exploration of the retrovirus led researchers to identify similarities between HIV and a retrovirus in African non-human primates that were then known as Simian Immunodeficiency Virus (SIV) (Gao et al., 1994). About 40 different primates, in Africa, are infected with SIV with some harboring multiple strain of SIVs (Apetrei et al., 2004). Phylogenetic analysis of SIV from African non-human primates and HIV in human provided remarkable understanding of viral transmission as zoonotic (Bailes et al., 2002) and evolution of the virus in human after transmission (Gao et al., 1999).

HIV is divided into two groups – HIV-1 and HIV-2 (Gao et al., 1999). Each group resulted from an independent cross species transmission from different African non-human primates to human (Sharp and Hahn, 2010). HIV-2 is discovered in 1986. This group is transmitted from sooty mangabey monkeys (Cercocebus atys) (Hirsch et al., 1989) and its prevalence is also high in the geographical location of these monkeys in West Africa (Santiago et al., 2005). Sooty mangabey monkeys are naturally infected by a strain of SIV (Hirsch et al., 1989). The phylogenetic analysis of HIV-2 strains shows that they closely group with the SIVsmm strain (Hirsch et al., 1989) that are non-pathogentic to its host monkeys (Gao et al., 1992). SIVsmm evolved in its host to produce multiple strains and subsequent multiple zoonotic transmissions from sooty mangabey monkeys to human (Hahn et al., 2000) gave rise to different subtypes of HIV-2. Although HIV-2 subtypes A to G are identified in human, it is assumed that more subtypes were introduced into human (Gürtler, 2004) but are lost for low adaptation fitness (Damond et al., 2004).

HIV-1 is the result of at least three cross species transmission events from chimpanzees (Pan troglodytes troglodytes (Ptt)) to human (Huet et al., 1990; Peeters et al., 1989). Phylogenetic analysis of HIV-1 sequences has shown that three independent cross transmission of the virus in to the human population, each giving rises to three sub groups: group M (Major), group O (Outlier) and group N (Non M or Non O) (Hahn et al., 2000; Keele et al., 2006). Recently a new HIV-1 strain, classified as group P, distinct from the previous three groups, has been discovered in a patient in Cameroon (Plantier et al., 2009).

Group M is the most prevalent and accounts for 98% of all infections (reviewed in (Sharp and Hahn, 2010)). Its epicenter is thought to be Kinshasha of present day Democratic Republic of Congo (Sharp and Hahn; Sharp and Hahn, 2010). Site stripping for clock detection method shows that group M and its closest simian relative branched out from their common ancestor in 17th century (Salemi et al., 2001) whereas molecular clock analysis of group M shows that the origin of it’s most recent common ancestor dates back to late 1920s (Korber et al., 2000). By 1960, long before human discovered its presence, HIV-1 group M had already diversified substantially (Worobey et al., 2008).

Group O and group N are rare and geographically confined to West African regions such as Cameroon and neighboring countries (Gao et al., 1999). It is still not understood about the non-pandemic characteristics of group O and N HIV-1 virus after the first zoonotic transmission (Ariën et al., 2005). It has been suggested that reduced replication capacity and transmission fitness are keys to their low prevalence(Ariën et al., 2005). Group O strain has at least 50% genetic identity with group M (Gürtler, 2004; VANDEN HAESEVELDE et al., 1996) and the molecular clock model of this group also showed that its origin dates back to 1920s (Lemey et al., 2004a). The date of origin of the introduction of group N into human population has been estimated to be in 1960s (Simon et al., 1998a). Phylogenetic analysis using genetic sequence under evolutionary pressure shows its close grouping with SIV from Chimpanzee (Corbet et al., 2000; Gao et al., 1999). This indicates that group N might be a recombinant strain of SIV and HIV-1 group (Simon et al., 1998a).

Group P is transmitted from gorilla as it is closely related to its SIV (Plantier et al., 2009). A study of HIV infected people in Cameroon shows its low prevalence of 0.06% (Vallari et al., 2011). Although HIV group P is discovery only in Cameroon and confined there, it can still be pandemic as it can adapt in human (Vallari et al., 2011).

### 1.4 HIV-1 Diversity

**1.4.1 HIV-1 subtypes**

HIV-1 group M is highly diversified and it is classified into nine subtypes: A, B, C, D, F, G, H, J and K (Figure 1.3) (Robertson et al., 2000b). The subtype classification is based on the phylogenetic and sequence distance analyses using gene sequence data forming major clades (Robertson et al., 2000b). “At least three epidemiologically unlinked sequences are required for defining a subtype” (Robertson et al., 2000a).



Figure 1.3: Phylogenetic tree showing HIV-1 group M diversification to subtypes A-D, F-H, J and K, inferred from nucleotide sequence alignments of gag, pol and env genes. Source: Robertson et al 2000 (Robertson et al., 2000a)

The classification of new subtype should also follow the same rule as “roughly equidistant from all previously characterized subtypes in all regions of the genome with a distinct pre-subtype branch similar to those of other subtypes” (Robertson et al., 2000b). The predominating group M subtypes are A, B, C and D (reviewed in (McCutchan, 2006)). The range of amino acid variation at gene level within a subtype and between subtypes differs from 15%– 20% and 25% - 35% respectively (Korber et al., 2001). Geographical locations of group M subtypes epidemic are show in Figure 1.4. The analysis from HIV samples collected from 70 countries in 2004 shows that “subtype C accounts for 50% of all infections worldwide” while subtypes A, B, G and D are found in decreasing order 12%, 10%, 6% and 3% respectively (Hemelaar et al., 2006). Subtypes F, H, J and K infections are rare and collectively account for only 0.94% infections (Hemelaar et al., 2006).

Subtypes can be further classified to sub-subtype based on a distinct sister clade formation (Gao et al., 2001) within a clade with the same rule of phylogenetic and distant analyses but not justifiable to call a subtype due to low genetic distance (Robertson et al., 2000b). Only subtypes A and F exhibit distinct sister clades (Gao et al., 2001). Subtype A has sub-subtypes A1 and A2 (A3 and A4 are mentioned by Taylor et al 2008(Taylor et al., 2008)); Subtype F has sub-subtypes F1 and F2 (Figure 1.3); sub-subtype F3 mentioned by Taylor et al 2008 (Taylor et al., 2008).

The lower diversity observed in Group N (Ayouba et al., 2000), O (Lemey et al., 2004b) and P (Vallari et al., 2011) correlate to low prevalence and geographical confinement to Western African countries such as Cameroon. It is still unclear if group O can be sub divided into subtypes (Roques et al., 2002). Group N as well does not show distinct sub clade within itself (Figure 1.5).

**1.4.2 HIV-1 recombination**

Initially, HIV-1 group M subtypes E (Artenstein et al., 1995; Tovanabutra et al., 2002; Wasi et al., 1995) and I (Figure 1.5) were also classified (reviewed in (McCutchan, 2006)). With availability of complete HIV genome sequence and phylogenetic analysis from it, the subtypes E and I were reclassified as circular

### 

Figure 1.4: HIV diversity around the globe, its level of prevalence in the area and number of genome sequenced. Source: McCutchan 2006




Figure 1.5: Neighboring joining phylogenetic tree showing HIV-1 group M, N and O. Group M shows distinct nine subtypes A-D, F-H, J, K while no specific subtype is observed in group N and O. Source: Letvin 2006 (Letvin, 2006)

recombinant forms CRF01\_AE (recombinant form of subtype A and E) and CRF04\_cpx (recombinant form of more than two subtypes, designated by “cpx”) respectively (reviewed in (McCutchan, 2006)). The same criterion of epidemiological unlinked isolates from three or more people applies for classification as a circular recombinant form (CRF) (Robertson et al., 2000a). A recombinant isolate discovered in single patient is termed as Unique Recombinant Form (URF) (reviewed in (McCutchan, 2006)). There are 55 CRFs listed in Los Alamos National Laboratory database for HIV sequences (<http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html>) as on July 22, 2013. The recombination breakpoints to shuffle HIV genome (Archer et al., 2008; McCutchan et al., 2002; Salminen et al., 1995; Zhang et al., 2010) from different strains of the virus are listed in <http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/breakpoints.html>, each appeared in a publication. CRFs account for at least 20% of all the HIV infections (Robertson et al., 2000a; Robertson et al., 1995; Sharp et al., 1995). CRF02\_AG is the most prevalent circulating recombinant form infecting over 9 million people on the whole (McCutchan, 2000) and geographically epidemic in the West African region (Figure 1.5). CRF01\_AE is the dominant circulating recombinant form in South-East Asia (Figure 1.5) (Taylor et al., 2008).

**1.4.3 Intra-patient HIV diversity**

HIV infection initiates mostly with a single virion (Fischer et al.; Keele et al., 2008). Evidences of multiple HIV variants transmission are also recorded (Long et al., 2000; Ping et al., 2000). Generally, HIV is genetically homogenous for a short post infection time (Delwart et al., 2002; Haase). In the long-term post infection period, virus replicates rapidly to produce genetically heterogeneous population (Long et al., 2000). This heterogeneous viral population consisting of a swarm of highly similar but genetically non-identical HIV viruses is called the HIV quasispecies (reviewed in (McCutchan, 2006)). It is observed that the diversity at a gene (*env*) in viral quasispecies can be approximately 30% (Fouchier et al., 1992). Factors that contribute to high genetic heterogeneity in viral quasispecies are high replication rate and turnover (Ho et al., 1995a), viral genome recombination (Fang et al., 2004; Gu et al., 1995; Lole et al., 1999), higher mutation rate by erroneous reverse transcriptase (Bebenek et al., 1989; Roberts et al., 1988), and host immune selection (Borrow et al., 1997; Price et al., 1997). On the whole, HIV replication (discussed in section 1.6) is the overall source of genetic heterogeneity in the viral population (reviewed in (Smyth et al.)).

Intra patientHIV genome recombination is a common event (Fang et al., 2004; Neher and Leitner). Two genomes from different viral strains from same subtype or different subtypes can be co-packed into single virion during replication (Stuhlmann and Berg, 1992). In the subsequent HIV replication, the ability of reverse transcriptase to switch between the two template genomes produces an intra subtype or inter-subtype recombined viruses at the end of the replication cycle (Ben-Artzi et al., 1996; Kostrikis et al., 2002). Genetic recombination allows rapid and efficient shuffling of advantageous genes and removing deleterious mutations, thus, increasing the viral fitness in the host (reviewed in (Smyth et al.)). Successful transmission of the recombinant forms with high viral fitness to three or more people and circulates in human population establishes Circulating Recombinant Forms (CRFs) (reviewed in (Perrin et al., 2003)), as discussed in section 1.4.2.

### 1.5 HIV genome and proteins – structures and functions

HIV has nine genes and produces 15 proteins (Frankel and Young, 1998). The genes are broadly grouped as accessory (vif, vpr, vpu and nef), structural (*pol*, *gag* and *env*) and regulatory (*tat* and rev). The higher number of proteins than genes is a result of post - transcriptional proteolysis of the products of structural genes (Frankel and Young, 1998).

**1.5.1 Accessory genes:**

Vif promotes the viral infectivity to the host, but has no role in viral production (Jager et al.). Vif is produced in the late stage of viral production (Sheehy et al., 2002; von Schwedler et al., 1993) to suppress the innate antiviral immunity of host (Madani and Kabat, 1998; Simon et al., 1998b). It is observed that vif is expressed only when the virus infects immune cells that express cytidine deaminase APOBEC3G (Navarro and Landau, 2004). The reason is that Vif protein prevents APOBEC3 proteins from hyper mutating HIV reverse transcripts as a mechanism of defense (Conticello et al., 2003; Mangeat et al., 2003; Mariani et al., 2003; Marin et al., 2003; Mehle et al., 2004; Schafer et al., 2004; Sheehy et al., 2003; Simon et al., 2005; Stopak et al., 2003; Wiegand et al., 2004; Zhang et al., 2003).

Vpr protein is packed in to nascent virions during budding out (Connor et al., 1995). Vpr is essential for viral core to enter and localize in the host cell nucleus after infecting the cell (Cohen et al., 1996). Vpr arrests the cell cycle during the transfer from G2 to M phase (Jowett et al., 1995; Rogel et al., 1995) by preventing the activation of the human p34cdc2/cyclin B complex (He et al., 1995). Vpr is also important for efficient viral replication in monocyte or macrophage cells, but T-cells (Connor et al., 1995).

Vpu is a protein unique to HIV-1 (Cohen et al., 1988) and is 16 kilo Dalton, 81 amino acids long (Strebel et al., 1988). Biological functions of vpu protein include degradation of CD4 in endoplasmic reticulum (Willey et al., 1992), interference of host immune cell MHC class II antigen presentation on the cell surface allowing the virus for host immune escape (Hussain et al., 2008; Nomaguchi et al., 2008) and viral maturation and release from host cell membrane (Klimkait et al., 1990).

Nef has no role in viral infectivity but plays a role during the biogenesis of viral particles (Laguette et al., 2009) and virulence (Lenassi et al.; Simmons et al., 2001). Nef down regulates the production of major histocompatibility complex type I (MHC type I) in the host cell (Blagoveshchenskaya et al., 2002; Greenberg et al., 1998; Lewis et al., 2012). This impairs the function of cytotoxic T lymphocyte cells to clear the infected cells (Adnan et al., 2006; Baur et al., 1994; Collins et al., 1998; Couillin et al., 1994; Sawai et al., 1994). Nef also down regulates CD4 on host cell surface (Garcia and Miller, 1991; Lama et al., 1999) and modulates cellular activation to evade host immune system (Baur et al., 1994; Sawai et al., 1994).

**1.5.2 Structural genes and proteins**

The Gag gene produces a precursor polyprotein (pr55gag) of ~ 500 amino acids long and weighs 55 kilodalton (Briggs et al., 2004). The Gag precursor has all the building blocks to form a fully infectious virion, even in the absence of other viral products (Wang and Barklis, 1993). A proteolytic cleavage of gag precursor yields the structural proteins – matrix, capsid, nucleocapsid and p6 (Figure 1.6) (Wiegers et al., 1998). The cleavage takes place in the nascent virus after budding out from host cell (Göttlinger et al., 1989). The matrix protein is at the N-terminal and p6 at the C-terminal of gag precursor (Borsetti et al., 1998; Wiegers et al., 1998).

All gag proteins play role at “post assembly and post processing stages in viral infectivity” (Wang and Barklis, 1993). In the HIV replication cycle, matrix domain of gag plays role in targeting gag precursor to the plasma membrane of the host cell and the viral assembly at the site (Dawson and Yu, 1998; Gheysen et al., 1989; Wang and Barklis, 1993; Zhang et al., 1998). The highly basic region in matrix mediates electrostatic association with phospholipids in plasma membrane during assembly (Chukkapalli et al.; Zhou and Resh, 1996). The capsid is a curved and closed shell consisting 250 hexamers and 12 pentamers (reviewed in (Briggs and Krausslich)). Capsid packs viral proteins, nucleocapsid and viral genome during assembly to pass on to new HIV particles (Ganser-Pornillos et al., 2004). Nucleocapsid plays role in efficient viral assembly by making pr55–pr55 inter-protein contacts (Dawson and Yu, 1998; Zhang et al., 1998) and localization of viral proteins (Larsen et al., 2008). P6 protein plays role in detaching and releasing the newly formed HIV particles (Demirov et al., 2002).

The *pol* polyprotein is produced by translational frame shift (Karacostas et al., 1993) (Figure 1.5), such that, as much as 241 nucleotides at 5’ region of the gene overlaps with 3’ region of *gag* gene (Jacks et al., 1988; Ratner et al., 1985). The proteolytic cleavage of *pol* precursor produces essential viral replication enzymes – protease (PR), reverse transcriptase (RT) and integrase (IN). The protease enzyme cleaves the *gag* and *pol* polyprotein to form the viral structure proteins and functional enzymes respectively (Darke et al., 1988b; ERICKSON-VIITANEN et al., 1989; Nutt et al., 1988). The reverse transcriptase enzyme reverse transcribes the viral RNA to produce a cDNA molecule after infecting host cell (Jacobo-Molina and Arnold, 1991; Sarafianos et al., 2009). The RNase H domain in RT degrades the viral RNA molecule following cDNA production (Davies et al., 1991). The integrase enzyme removes two bases from 3’ DNA molecule and functions strand transfer during the process of integrating the proviral DNA into the host genome (Pruss et al., 1994).




Figure 1.6: HIV genes and proteins positions in the viral genome and their viral parts. Source: Frankel and Young 1998 (Frankel and Young, 1998)

The *env* gene produces a precursor glycopolyprotein (gp160) that is processed at post-translational by human convertase enzymes - PC1 and furin to produce glycoprotein 120 (gp120, HIV-1 SU) and glycoprotein 41 (gp41, HIV-1 TM) (Decroly et al., 1994). Gp120 is a non-covalent complex of external protein and gp41 is a trans-membrane protein; both play vital role for initial steps in viral infection (Chan et al., 1997). Three gp120 molecules bound with three gp41 molecules to form envelop spikes (Pancera et al.). They are organized to form trimeric complexes on the surface of HIV and mediate HIV entry into the host cell (Liu et al., 2008). The exposed external complex gp120 binds to the CD4 receptor on the host immune cell (Rizzuto et al., 1998). This triggers a conformational shift of trimeric complex that enables a conserved gp120 region binding to a chemokine receptor, either CCR5 or CXCR4, to facilitate fusion of the viral and host membranes (Huang et al., 2007; Rizzuto et al., 1998; Wu et al., 1996; Wu et al., 1997). The gp120-CD4 complex also triggers conformational change in gp41 trans-membrane protein from native non-fusion state to fusion state (Chan et al., 1997; Kliger et al., 1997). Gp41 plays role in the viral fusion and release of viral contents in to the host cell (Furuta et al., 1998; Melikyan, 2008),. The gp41 consists of heptad repeats - HR1 and HR2 that play role in fusion process (Furuta et al., 1998; Tan et al., 1997). HR1 is a bundle of three helical motifs and HR2 is trimeric coiled coil structure (Dwyer et al., 2003). During fusion process, HR2 makes numerous contacts with HR1 to form stable six helical bundles (Melikyan et al., 2000).

**1.5.3 Regulator Genes:**

*Tat* is a trans-activating factor localized in the nucleus for HIV gene expression (Rosen and Pavlakis, 1990a; Roy et al., 1990). The HIV proviral genome integrated in to the host genome is regulated by cellular as well as the viral transcription regulatory factors (Cullen, 1991; Gaynor, 1992). Tat is the primary transcriptional regulatory factor (Marcello et al., 2001). An example of Tat action is the control of RNA polymerase II elongation during transcription, which otherwise disengages from the template DNA strand, terminating the transcription prematurely (Bourgeois et al., 2002; Chou et al.; He and Zhou). Sodroski *et al*. (1985) first explained the function of Tat (Sodroski et al., 1985).

Rev is a 19 kilo Dalton phosphoprotein (Malim et al., 1989a) trans-activating factor for HIV gene expression (Rosen and Pavlakis, 1990a). Like Tat, it is also mainly localized in the nucleus of host cell (Rosen and Pavlakis, 1990b), but cycles rapidly between the nucleus and cytoplasm as it promotes nuclear export of the transcriptional products (Fischer et al., 1995; Fischer et al., 1994; Henderson and Percipalle, 1997; Malim et al., 1989b). Rev binds at the Rev Responsive Element (RRE), which is an RNA element encoded within the *env* region of the virus (Daly et al., 1989; Malim and Cullen, 1991).

### 1.6 HIV replication

There are 11 major events in HIV’s replication cycle (Figure 1.7). The initial step of viral entry in to a host immune cell includes HIV gp120 molecule binding to CD+ receptor followed by binding to a co receptor on the surface of the host cell and fusion of the viral and host cell membranes (see section 1.5.2 for more detail).

Following the fusion, the viral core enters in to the cytoplasm of host cell. The reverse transcriptase enzyme reverse transcribes the RNA molecule to cDNA (Figure 1.7 step 2) in the intact capsid of the viral core (McDonald et al., 2002). The reverse transcriptase enzyme is not perfect at copying mRNA molecule to cDNA and has no capability for error correction (Bebenek et al., 1989; Bebenek et al., 1993; Preston et al., 1988; Roberts et al., 1988). The rate of errors generated is by reverse transcriptase is in the order of 10-5 per base per replication cycle (Mansky and Temin, 1995). This is a crucial step as it contributes to generation of variations in the viral quasispecies (reviewed in (Goodenow et al., 1989; Nowak et al., 1990)).

Subsequently the capsid is dissembled, termed as uncoating (McDonald et al., 2002; Shah et al., 2013), releasing the ribonucleoprotein complex in to the cytosol (Dismuke and Aiken, 2006). The process can take an hour or less since time of post infection (Hulme et al., 2011). The capsid and nucleocapsid proteins dissociate from cDNA but the reverse transcription complex remains intact along with viral matrix, integrase, vpr and human protein high mobility group I (HMG I (Y)) forming pre-integration complex (PIC) (Bukrinsky et al., 1993; Farnet and Haseltine, 1991; Miller et al., 1997). The PIC protects cDNA from endonuclease degradation (Miller et al., 1997). In an ATP dependent process (Bukrinsky et al., 1992), PIC is transported on host microtubules towards the nuclear membrane (McDonald et al., 2002). Integrase assists in nuclear import in association with nuclear import machinery like importin (Fassati et al., 2003) and transportin-SR2 (Christ et al., 2008). It is now established that central polypurine tract-central termination sequence (cPPT-CTS) plays role in kinetics of nuclear import (Riviere et al.).

Post-nuclear entry, integrase processes the viral DNA for integration (LaFemina et al., 1992) (Figure 1.7 step 5) into host genome as explained in section 1.5.2. Host transcriptional co-factor LEDGF/p75 and HIV integrase interact to tether to the host chromosome during the integration process (Emiliani et al., 2005).

The integrated HIV provirus hijacks the host cell transcriptional machinery for viral genes to transcribe (Figure 1.7 step 6) (Davey et al., 2011). HIV protein Tat promotes the transcription of the viral DNA (Ott et al., 2011; Razooky and Weinberger, 2011). The viral transcriptome encodes structural proteins, accessory proteins and viral enzymes necessary for a complete functional HIV (reviewed in (Karn and Stoltzfus)).

The viral Rev protein facilitates exporting (Figure 1.7 step 7) of the unprocessed viral transcriptome to cytoplasm for translation (Malim et al., 1989b). HIV has no translation system of its own; the host translational machinery is exploited for translation (Figure 1.7 step 8) of the viral transcriptome to its proteome (Cherry et al., 2005; Thompson and Sarnow, 2000).

Upon translation of all viral proteins, viral *gag* initiates virion assembly (Figure 1.7 step 9) at the cell membrane (Dong et al., 2005; Nermut et al., 1998; Saad et al., 2006). The complete assembled virion particles bud out and are released (Figure 1.7 step 10) from the plasma membrane by the host ESCRT machinery involving Tsg101 and ALIX regulatory proteins (Fujii et al., 2007; Garrus et al., 2001; Saksena et al., 2007). The maturation (Figure 1.7 step 11) of the nascent HIV virions begins concomitantly with budding out (Klimkait et al., 1990; Schubert et al., 2000). *Gag* and *Pol* polyproteins are proteolytically cleaved by protease enzyme in the maturation step (Darke et al., 1988; Pettit et al., 2005).




Figure 1.7: The HIV replication cycle showing major stages. Viral proteins that play role in each event are colored blue. (Source: modified from Ho and Bieniasz 2008) (Ho and Bieniasz, 2008)

Each HIV replication cycle releases new infectious virions in the order of 109 per day (Ho et al., 1995b). The number of new infecting HIV determines the replication rate of the virus (Tersmette et al., 1989). A long post infection period shows higher turnover rate associated with CD4+ cell depletion and viral population expansion (Ho et al., 1995b).

### 1.7 Antiretroviral Drugs

**1.7.1 Reverse Transcriptase Inhibitors**

1. **Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**

NRTIs are analogs of nucleotides but without 3’ hydroxyl group (reviewed in (Sarafianos et al., 2004)). The drug is taken in unphosphorylated form, which cytokinases phosphorylates to form 5’ triophosphates (reviewed in (De Clercq, 2002; Ilina and Parniak, 2008)). This then, leads to the incomplete termination of HIV-1 cDNA synthesis (Sluis-Cremer et al., 2000). The action of the drugs is shown in Figure 1.8 and the list of approved NRTI drugs shown in Table 1.1.

1. **Non-nucleoside reverse transcriptase inhibitors (NNRTIs)**

NNRTIs specifically bind at an allosteric site 10 [Å](http://en.wikipedia.org/wiki/%C3%85) from the polymerase active site of the HIV-1 reverse transcriptase (Himmel et al., 2006; Sarafianos et al., 2009), close to the substrate-binding site. The binding induces conformational changes in the enzyme, which distorts the catalytic aspartate triad of its active site and inhibits the function of the enzyme (Figure 1.9) (Balzarini, 2004; Esnouf et al., 1995). The list of approved NNRTI drugs is shown in Table 1.1


****

Figure 1.8: Mechanisms of NRTI drug to inhibit revere transcriptase. Nucleoside analogs lacking 3’ hydroxyl group is incorporated in growing chain of drug sensitive virus resulting in incomplete termination of viral cDNA. Source: Adapted from (Clavel and Hance, 2004)


****

Figure 1.9: Mechanism of NNRTI drugs to inhibit reverse transcriptase. The drugs bind to drug sensitive viral reverse transcriptase disabling its function. Source: Adapted from (Clavel and Hance, 2004)

Table 1.1: Antiretroviral drugs used in the treatment of HIV infection, their mechanisms of action and mechanisms of resistance. Source: Adapted from François Clavel and Allan J. Hance 2004 (Clavel and Hance, 2004) and (Ammaranond and Sanguansittianan, 2012; Colin et al., 2013)

| **Drugs** | **Mechanism of Action** | **Mechanisms of Resistance** |
| --- | --- | --- |
| **Fusion and entry inhibitors** | | |
| Enfuvirtide (T-20) | 36 amino acid peptide derived from the HR2 domain of glycoprotein 41  Interferes with glycoprotein 41 dependent membrane fusion | Mutations affect HR1, a domain of glycoprotein 41 whose interaction with HR2 promotes membrane fusion |
| Maraviroc | Binds to CCR5 co receptor | Development of CXCR4 using HIV HIV-1 exploits CCR5 conformational heterogeneity |
| **Nucleoside reverse transcriptase inhibitors (NRTls)** | | |
| Zidovudine (AZT) | Analogues of normal nucleosides  Active as triphosphate derivatives  Incorporated into nascent viral DNA  Prematurely terminate HIV DNA synthesis | Thymidine analogue mutations promote ATP-mediated and pyrophosphate-mediated excision of the incorporated terminator |
| Didanosine (ddl) |
| Zalcitabine (ddC) |
| Stavudine (d4T) |
| Lamivudine (3TC) |
| Abacavir (ABC) |
| Tenofovir disoproxil (TVD) |
| Emtricitabine (FTC) |
| **Nucleotide reverse transcriptase inhibitors (NtRTls)** | | |
| Tenofovir | Same as nucleoside analogues | K65R impairs incorporation of tenofovir into DNA  Thymidine analogue mutations often associated with cross-resistance to tenofovir |
| **Non-nucleoside reverse transcriptase inhibitors (NNRTls)** | | |
| Nevirapine (NVP) | Bind a hydrophobic pocket of HIV type 1 reverse transcriptase  Block polymerization of viral DNA  Inactive against HIV type 2 | Mutations reduce affinity of the inhibitors for the enzyme  Single mutations generally sufficient to induce high level of resistance |
| Delavirdine (DLV) |
| Efavirenz (EFV) |
| Etravirine (ETR) |
| **Protease Inhibitors (PI)** | | |
| Saquinavir (SQV) | Structure derived from natural peptidic substrates of the HIV type 1 protease  Bind the active site of the protease | Mutations reduce affinity of the inhibitors for the enzyme  High-level resistance requires a accumulation of mutations |
| Ritonavir (RTV) |
| Indinavir (IDV) |
| Nelflnavir (NFV) |
| Amprenavir (APV) |
| Lopinavir + Ritonavir (LPV/r) |
| Fosamprenavir (FPV) |
| Tipranavir (TPV) |
| Darunavir (DRV) |
| Atazanavir (ATV) |
| **Integrase Inhibitors** | | |
| Raltegravir | Binds selectively to the enzyme complexes that results in inhibiting strand transfer of viral and host DNA | Mutations at conserved carboxylate residues (Asp64 and Asp116) |

**1.7.2 Protease Inhibitors (PI)**

Protease Inhibitors interfere with the cleavage of the *gag*-*pol* polypeptide (Seelmeier et al., 1988) as competitive peptidomimetic inhibitors. The hydroxyethylene core in the inhibitors prohibits the cleavage action of the HIV protease enzyme (Vacca et al., 1994; Vacca et al., 1991). However, as an adverse side effect, patients that have used these inhibitors have developed lipodystrophy and hyperlipidemia (Carr et al., 2000; Carr et al., 1998a; Carr et al., 1998b, c; Liang et al., 2001; Miller et al., 2000; Tsiodras et al., 2000).

**1.7.3 Integrase Inhibitors**

The feasibility and efficacy of integrase inhibitors have been tested in Rhesus Macaques (Hazuda et al., 2004). Most of the integrase inhibitors target the strand transfer function of the enzyme (Bera et al., 2011; Espeseth et al., 2000; Hazuda et al., 2000; McColl and Chen, 2010; Pannecouque et al., 2002). An X-ray structure of the integrase enzyme has revealed the active site model of the enzyme complexes with the DNA (Chen et al., 2008). The only integrase inhibitor that has shown a promising antiretroviral effect is Raltegravir, which was tested on animal models and is currently undergoing clinical trials (reviewed in (Ammaranond and Sanguansittianan, 2012)).

**1.7.4 Cell entry inhibitors**

The cell entry inhibitors interfere with the viral binding or fusion of HIV to a host cell. The two classes of cell entry inhibitors are listed below:

1. **CCR5 co receptor antagonist:**

Maraviroc is the only CCR5 antagonist in clinical use (De Clercq, 2005a, b; Fätkenheuer et al., 2005; Rosario et al., 2005; Rosario et al., 2006; Wheeler et al., 2007). It is also the only antiretroviral drug that does not target any viral enzyme or protein molecule but, instead, binds to the host cell receptor CCR5 (Westby and van der Ryst, 2005). This binding prevents HIV gp120 binding to the co-receptor, thereby disabling the viral entry in to the cell (Fätkenheuer et al., 2005). However, it is important to carry out an HIV tropism test for the viral co-receptor use, before administrating this drug, as the drug is ineffective against CXCR4 co receptor using viruses (Raymond et al., 2010).

1. **Fusion Inhibitors**

Fusion inhibitor design is based on targeting the heptad regions HR1 or HR2 of gp41, which prevents HIV from creating a fusion pore on host cell membrane (reviewed in (Baldwin et al., 2003)). Enfuvirtide (Duffalo and James, 2003; Poveda et al., 2005) is a synthetic peptide, approved for clinical use in 2003 (Robertson, 2003), which can bind to the gp41 HR1 region (Wild et al., 1993). However the emergence of Enfuvirtide resistant viral strains lead to its discontinuation for clinical use in 2004 (Briz et al., 2006). Sifuvirtide is another HIV fusion inhibitor peptide under research (Wang et al., 2009).

### 1.8 HIV Treatment

### 1.8.1 Brief history of antiretroviral treatment

The treatment of HIV infection was a great challenge and faced failures in the initial years (Sandstrom and Kaplan, 1987). In 1985, an assay for diagnosis of HIV antibody was developed for the confirmation of HIV infection (Ward et al., 1986). Clinical treatment for those with confirmed HIV infection started with the only available NRTI drug – azidothymidine (AZT), (later called Zidovudine (ZDV)). The drug is characterized for its toxic and unpleasant side effects (Koch et al., 1992; Richman et al., 1987). Nonetheless, the drug was the only hope for HIV infected people at the chronic stages of infection in mid 1980’s and was approved for use but the survival




Figure 1.10: The time line of approved HIV antiretroviral drugs. Source: (Palmisano and Vella, 2011)

benefits lasted less than a year (Fischl et al., 1993; Fischl et al., 1990; Lundgren et al., 1994; Volberding et al., 1995; Volberding et al., 1990). Other NRTI drugs including didanosine (ddI) in 1991, Zalcitabine (ddC) in 1992, stavudine (d4T) in 1994 and lamivudine (3TC) in 1995 - were approved for use (Figure 1.10) but were toxic as well. The administration of the drugs was altered to reduce the toxicity of each drug but the approach remained ineffective (Skowron et al., 1993). Then, a combination therapy two NRTI drugs (Saravolatz et al., 1996), for example zidovudine with didanosine or zalcitabine showed some improvement, characterized by increased CD+ and better survival but with less durability and poor tolerability (Hammer et al., 1996). Triple NRTI combination therapy containing 3TC, ZDV and d4T was better tolerated but could not control HIV reproduction (Kuritzkes et al., 1999). A good result obtained from using NRTI drugs was the substantial reduction in HIV transmission from mother to child at birth (Connor et al., 1994; McGowan and Shah, 2000; McIntyre et al., 2009).

A notable advancement in antiretroviral treatment was observed after the development of NNRTI drugs and PI drugs that interacted directly with the viral proteins reverse transcriptase and protease to inhibit their action. Clinical trials were conducted with triple combination therapy contained 2 NRTIs and a NNRTI drug or 2 NRTIs and a PI drug (Montaner et al., 1998a; Montaner et al., 1998b; Staszewski et al., 1999b). Besides antiretroviral activity, combination therapy was also studied for toxicity and tolerability (Montaner et al., 1998b; Staszewski et al., 1999a; Staszewski et al., 1999b). The triple combination therapy of Nevirapine/efavirenz (NNRTI drug) with two NRTI drugs showed a good viral suppressing result (Staszewski et al., 1999a; Staszewski et al., 1999b) and was superior to monotherapy and dual therapy (Robbins et al., 2003).

A drug cocktail with 2 NRTIs and a protease inhibitor showed highly effective result (Cameron et al., 1999; Merry et al., 1997) with viral suppression time longer than the study period (Gulick et al., 2000; Hammer et al., 1997). The concept of highly active antiretroviral therapy was conceived after the cocktail of 3 drugs from different classes showed effective results (Gulick et al., 1998; Gulick et al., 1997; Hammer et al., 1997). The success of triple drug therapy was reported in Vancouver AIDS conference in 1996. In a short time, recommendations for antiretroviral therapy were published to manage HIV infections (Carpenter et al., 1997). More drugs from NRTI, NNRTI and protease inhibitors were developed with lower toxicity and higher potency than the earlier drugs. After years of researching different drug combination, the first drug regimen for ‘standard-of-care’ is available consisting of two NRTI drugs and a third drug from any other drug class (Vella et al., 2012).

### 1.8.2 Treatment guideline

The World Health Organization (WHO) has produced the clinical guideline (<http://www.who.int/hiv/pub/guidelines/arv2013/art/en/index.html>) for HIV treatment. From the treatment point of view, the guideline has grouped HIV infected individuals as adult, pregnant and breast feeding women, children less than 3 years old, children 3 or more years old and HIV people co-infected with other diseases. Regardless of the grouping, the guideline recommends treatment initiation to all confirmed HIV infected people with CD4+ cell count less than or equal to 350 cells/mm3 in resource poor countries and less or equal to 500 cells/mm3 in resource rich countries. However, where laboratory tests for CD4+ count may not be feasible, the WHO clinical stages should be used as a guide for treatment initiation (Weinberg and Kovarik, 2010).

The WHO antiretroviral guideline recommends a combination of 2 NRTIs and 1 NNRTI as first line therapy. The addition of a protease inhibitor is recommended for children below 3 years old. On virologic failure to first line treatment, a second line drug regimen containing 2 NRTIs and a ritonavir boosted protease inhibitor is recommended. Following failure to second line therapy, a new drug class – the integrase inhibitor is introduced in third line therapy along with a reverse transcriptase and a protease inhibitor.

Patients undergoing ART therapy are monitored for effectiveness of the treatment at a defined interval. Laboratory tests for viral load should be done for monitoring the treatment response. A viral load of greater than 1000 viral RNA copies/ml blood sample indicates virologic failure to the treatment and the patient is recommended to switch to new drug regimen (Figure 1.11). If a viral load test is not feasible routinely, CD4+ count and clinical monitoring need to be used (Weinberg and Kovarik, 2010).

### 1.9 HIV Drug Resistance

Currently there are 20 approved antiretroviral drugs that include 8 PIs, 7 NRTIs, 4 NNRTIs and 1 integrase inhibitor. For more details on antiretroviral drugs, see section 1.7. Antiretroviral treatment using a drug or a combination of different class drugs, results in drug failure at certain time point. For more details see section 1.8.1. Drug failure correlates with emergence of drug resistant HIV variants (Figure 1.1). The error prone nature of the reverse transcriptase (di Marzo Veronese et al., 1993; Dumonceaux et al., 1998) and high turnover (Mansky, 1996; Mansky and Temin, 1995) are two major driving forces that result in multiple mutations conferring resistance to the drug (Kellam et al., 1994; Larder et al., 1991; Larder and Kemp, 1989; Tisdale et al., 1993). Drug resistance was first observed for patient receiving zidovudine monotherapy (Larder et al., 1989b; Rooke et al., 1989).




Figure 1.11: Dynamics of HIV viral load within an infected patient. The viral load peaks at acute infection followed by a significant drop due to a lower CD4+ count. The introduction of highly active cocktail of anti retroviral drugs arrest the viral replication cycle and decreases the viral load to safe level. Spontaneous mutations give rise to resistant viruses that replicate with high turnover increasing the viral load and the therapy fails. The interruption of drugs contributes to a higher viral load. The introduction of second line anti retroviral drugs suppresses the viral load back to safe levels again and the cycle of viral load repeats itself. Source: Roger Paredes personal communication




Figure 1.12: Development of HIV drug resistance against NNRTI. The accumulation of drug resistant mutations changes three-dimensional confirmation of a viral protein, disabling drug binding and carrying out its normal function. Source: (Clavel and Hance, 2004)

This drug resistance led to the development of AIDS defining symptoms and numerous deaths in HIV infected people in the monotherapy (D'Aquila et al., 1995; Japour et al., 1995; Kahn et al., 1992). Zidovudine experienced individuals were observed to show poor virologic response when changed to didanosine monotherapy or a combination of didanosine and lamivudine (Miller et al., 1998) or stavudine and lamivudine (Montaner et al., 2000). The combination of two drugs was the method of strategy to tackle drug resistance. Where a combination of drugs showed improved treatment outcome (Collier et al., 1993; Eron et al., 1995; Shafer et al., 1995; Shafer and Merigan, 1995), it resulted in a virologic resistance response after 2 years (Shafer et al., 1995). This was due to the baseline HIV-1 drug resistance mutations, which caused therapeutic drug failure (Van Vaerenbergh et al., 2000). The multidrug resistance mutations, selected by the dual combination therapy, are resistant to both drugs used in the treatment (Shirasaka et al., 1995).

HIV replication was suppressed for longer time than earlier therapies after the introduction of NNRTI drugs or protease drugs, or both inclusive triple combination therapies (Collier et al., 1996; Montaner et al., 1998b; Staszewski et al., 1999b). NRTI, NNRTIs, particularly nevirapine or efavirenz and a protease inhibitor included triple combined therapy could suppress the viral replication and reduce HIV to an undetected level (Havlir et al., 1998) but resulted in failure after development of multiple resistant mutations against the drugs (Casado et al., 2000; Hanna et al., 2000). The NNRTI resistant mutations change the reverse transcriptase structure that disables the drug binding to the enzyme (Figure 1.12). Suboptimal therapy, often due to low adherence, leads to drug failure (Bangsberg et al., 2007). This limits the therapy options and drug failure with new combinations in short time (Hammer et al., 2008). Even the combination therapy of five drugs including 2 NRTIs, one NNRTI and 2 PIs resulted in poor virologic response in just 24 weeks (Piketty et al., 1999).

These studies also show that the percentage drug resistance can be heterogeneous and that suggests the necessity of drug resistance testing before initiating antiretroviral therapy (Hanna and D'Aquila, 2001).

Phenotypic and genotypic assays are available for drug resistance testing. A phenotypic assay includes viral stock generation from peripheral blood mononuclear cells (PBMCs), titration of stock to get viral infectivity, infection of cell culture with known concentrations of antiretroviral drugs and calculation of inhibitory concentration (IC) 50 and 90, based on a measure of infection. The limitations of the method include: its labor intensive, minimum of six weeks time requirement, in vitro viral selection pressure during the assay period and use of PBMCs only (not virus in plasm) for drug susceptibility test (Hanna and D'Aquila, 2001).

The limitations led to development of HIV resistance assays based on recombination of the virus from plasma samples (Hertogs et al., 1998; Kellam and Larder, 1994; Martinez-Picado et al., 1999; Petropoulos et al., 2000; Shi and Mellors, 1997). The recombinant assays are based on extraction of the plasma viral genome, amplification of PR and RT regions, insertion of the sequence into a HIV vector to produce recombinant virus that are used for infection of cell culture on which drug susceptibility test is done at IC50 and IC90. Antivirogram assay (Virco, Mechelen, Belgium) (Hertogs et al., 1998) and PhenoSense assay (ViroLogic, South San Francisco, California) (Petropoulos et al., 2000) are two automated recombinant assays; both require up to 10 days to complete the resistance test. These assays sample the predominant variant in the viral population while minor variants may go undetected that could lead to drug failure (Simen et al., 2009). The assays involve complexities and are expensive (reviewed in (Hirsch MS, 2000)).

Genotypic assays are based on mutations inferred from gene sequences. Specific mutations in HIV-1 provide resistance to related antiretroviral drugs (Figure 1.13 and Figure 1.14). The HIV test sequence can be compared with a database of known drug resistant viral specimens e.g. the Stanford HIV database (Rhee et al., 2003). The information that the mutations in HIV-1 test sequence similar to known resistant viral sequences can be used to infer the drug susceptibility classed as susceptible, resistant and intermediate resistant (Larder et al., 1999; Mayer et al., 2001).

Sanger based technology has been the standard for sequencing HIV-1 genes for drug resistance genotyping. For more details on Sanger technology based HIV-1 resistance test will be discussed in section 1.10. Oligonucleotide hybridization based genotypic assays, as in GeneChip (Affymetrix) (Kozal et al., 1996) and LiPA (InnoGenetics) (Stuyver et al., 1997), were in used but limited to preselected drug resistant mutation codons.

### 1.10 HIV genotyping for Resistance Test

### Conventional Population Based HIV Drug Resistance Genotyping

The pattern of drug resistant mutations (Figure 1.13 and Figure 1.14) in HIV has strong relation with virologic failure (Condra et al., 1995; Larder et al., 1989a; Larder and Kemp, 1989; Lorenzi et al., 1999; Molla et al., 1996; van Leeuwen et al., 1995; Zolopa et al., 1999) and can be used for antiretroviral therapy optimization for virologic benefits in clinical settings (Baxter et al., 2000; Durant et al., 1999; Van Vaerenbergh, 2001). Conventional HIV genotyping includes Sanger dideoxy termination based population sequencing (Ewing et al., 1998; Metzker, 2005; Sanger et al., 1977).



Figure 1.13 Mutations in HIV-1 reverse transcriptase gene by codon positions that is associated with resistance to reverse transcriptase inhibitors. Source: Adapted from Johnson et al 2013 (Johnson et al., 2013)




Figure 1.14: Mutations in HIV-1 protease gene by codon positions that is associated with resistance to protease inhibitors. Source: Adapted from Johnson et al 2013 (Johnson et al., 2013)

The technology outputs a chromatogram that shows a peak for all the bases at a particular position of a gene sequence for viral population (Struck et al., 2012). The sequence of the mixed population is determined based on the peaks generated for the bases called. At the position of nucleotide mixture, besides the highest peak, the lower peaks with greater or equal to 20% height of the highest peak are also marked and the ambiguous base representing the marked bases are added to the sequence (Woods et al., 2012). Thus, conventional population based sequencing method has limited sensitivity; the low frequent variants below 20% are not detected reliably (Ji et al., 2011; Johnson and Geretti; Palmer et al., 2005); and it underestimates the total number of variants in the viral population (Palmer et al., 2005). Undetected low frequency HIV variants are clinically significant as they are usually drug resistant (Paredes et al.; Rowley et al.; Simen et al., 2007; Simen et al., 2009a). Those minor variants rebound in the presence of drugs, leading to ultimate virologic failure (Paredes et al.; Rowley et al.). This necessitates improved and highly sensitive sequencing technologies able to detect minor HIV variants in the viral quasispecies (reviewed in (Metzker, 2009)).

### 1.11 Next Generation Sequencing technologies

The sequencing technologies developed with much higher throughput than automated Sanger sequencing are known as Next Generation Sequencing (NGS) technologies. Commercially available NGS technologies in the market are Roche/454, Illumina, Applied Biosystems SOLiD technology and Ion torrent). The NGS systems differ in yield, sequencing error rate, read length, sequencing time (Table 1.2), sequencing chemistry and sequencing cost (reviewed in (Metzker, 2009b; Shendure and Ji, 2008)); and that each NGS outperforms the others at a particular application (Shokralla et al., 2012).

Roche/454 and Illumina implement a ‘Sequencing by synthesis’ (SBS) technique for DNA sequencing (Margulies et al., 2005b). DNA fragments are PCR amplified to million copies such that while sequencing, simultaneous addition of million bases, one to each growing strand of template fragment, emits detectable fluorescent light (Margulies et al., 2005a). A defined order of free nucleotide molecules are flowed in the reaction plate, nucleotides are allowed to incorporate, fluorescent light is detected and any unincorporated nucleotides are washed off for next cycle. Roche/454 and Illumina differ only at the sequencing step. In Roche/454, polymerase continues nucleotide addition reactions until the base flowing in the reaction plate is complementary to the template sequence. The intensity of fluorescent light emission is detected and is proportional to the number of bases subsequently added, as a homopolymer run, in a particular reaction cycle (Margulies et al., 2005b). In the homopolymer region (repetition of a base over 3 times) the light intensity and the bases added can be disproportionate, generating high insertion or deletion (indel) errors (Loman et al., 2012; Luo et al., 2012) at the rate of 0.38 per 100 bases (Loman et al., 2012). Illumina, on the other hand, stops the reaction after single nucleotide addition, detects the color of light emission that depends on a base (Bentley et al., 2008) but has base calling biases, generating substitution errors (Luo et al., 2012). The major advantage of Illumina over other systems is that it has the highest throughput (Table 1.2). The sequencing chemistry of the systems impacts on sequence read length. Roche/454 yields a lower number of sequences but the longest read length (up to 800 bases) (Table 1.2). The longer read length can reveal the drug

Table 1:2 Comparative analysis of different NGS systems. Source: adapted from Shokralla et al 2012 (Shokralla et al.), Niedringhaus et al 2011 (Niedringhaus et al.) and Glenn 2011 (Glenn, 2011)

| Platform | Read length (bp) | Reads/run | Sequencing output/run | Run time | Advantages | Primary applications |
| --- | --- | --- | --- | --- | --- | --- |
| Roche/454 GS FLX | 400–500 | 1 × 106 | ≤500 Mb | 10 h | Longest read lengths among 2nd generation, high throughput compared to 1st generation sequencing | 1\*, 2, 3\*, 4, 7, 8\* |
| Roche/454 GS FLX+ | 600–800 | 1 × 106 | ≤700 Mb | 23 h |
| Roche/454 GS Junior | 400–450 | 1 × 105 | ∼35 Mb | 10 h |
| Illumina HiSeq 2000 | 100–200 | 6 × 109 | ≤540–600 Gb | 11 d | Very high throughput | 1\*, 2, 3\*, 4, 5, 6, 7, 8 |
| Illumina HiSeq 1000 | 100–200 | 3 × 109 | ≤270–300 Gb | 8.5 d |
| Illumina GAIIx | 50–75 | 6.4 × 108 | ≤95 Gb | 7.5–14.5 d |
| Illumina MiSeq | 100–150 | 7 × 106 | ≤1–2 Gb | 19–27 h |
| AB SOLiD 5500 system | 35–75 | 2.4 × 109 | ∼100 Gb | 4 d | Very high throughput; lowest reagent cost needed to reassemble a human genome among the widely accepted 2nd generation platforms, lower error rate | 3\*, 5, 6, 8 |
| AB SOLiD 5500 xl system | 35–75 | 6 × 109 | ∼250 Gb | 7–8 d |
| Ion Torrent -314 chip | 100–200 | 1 × 106 | ≥10 Mb | 3.5 h | Direct measurement of nucleotide incorporation events; DNA synthesis reaction operates under natural conditions (no need for modified DNA bases) | 1, 2, 3, 4, 8 |
| Ion Torrent -316 chip | 100–200 | 6 × 106 | ≥100 Mb | 4.7 h |
| Ion Torrent -318 chip | 100–200 | 11 × 106 | ≥1 Gb | 5.5 h |

Bold indicates applications that are most often used, economical or growing

1 = de novo BACs, plastids, microbial genomes. 2 = transcriptome characterization.

3 = targeted re-sequencing. 4 = de novo plant and animal genomes.

5 = re-sequencing and transcript counting. 6 = mutation detection.

7 = metagenomics. 8 = other

\*Pooling multiple samples with sequence tags (i.e. MIDs) is required for efficient use of this application

resistant mutations patterns in a particular variant, which is a huge advantage of Roche/454 compared to other NGS systems for HIV-1 resistance genotyping.

Applied Biosystems SOLiD implements a ‘Sequencing by ligation’ technique for DNA sequencing, thus bypassing any DNA polymerase related sequencing errors (Pandey et al., 2008). The template DNA is amplified in similar way to previous NGS technologies. During sequencing, a universal primer and a library of pre-designed 1,2-probes of 8 nucleotides (or dibase probe) along with a DNA ligase enzyme, is added. The probes hybridize to the complementary template sequence and the fluorescence of the probe is read. The probe hybridization is repeated for seven cycles extending read length to only 35 bases; which is not desirable from a perspective of HIV-1 genotypic drug resistance test. In the next cycle, a new universal primer is hybridized at an offset position of one base (n-1) to the previous primer position followed by a ligation sequencing process. The primer resetting cycle is repeated five times providing dual measurements of each base and the final sequence is decoded from color code information using 4 by 4 color code (reviewed in (Mardis, 2008)).

Ion torrent technology implements sequencing by synthesis method and electronic sensors connected to complementary metal-oxide-semiconductor integrated circuit are used with a microprocessor for signal processing (Jakobson et al., 2002; Milgrew et al., 2004). The sequencing step is similar to Roche/454 homopolymer sequencing but the base detection is completely electronic, and that reduces the ion torrent cost lower than other systems (Glenn, 2011). During DNA sequencing, a base incorporation releases a hydroxyl ion (H+) that shifts the pH of the surrounding solution and this correlates directly to the number of nucleotides incorporated in that particular base flow cycle (reviewed in (Niedringhaus et al., 2011). This change in pH is detected by a sensor at the bottom of each well, converted to a voltage and digitalized by semi conductor CMOS integrated circuits (Pennisi, 2010). Signal processing software is used to convert the data for measurement of base incorporations in that flow using a physical model (Rothberg et al., 2011). The final sequences generated, after processing, have the read length up to 200 bases (lower than Roche/454) but like Roche/454, Ion torrent sequences have indel errors at homopolymer regions at rate of 1.5 per 100 bases (Loman et al., 2012).

### 1.12 HIV-1 Drug resistance Genotyping in the era of ultra-deep high throughput sequencing

As the conventional genotyping method is unable to characterize the clinically relevant minor variants in the viral quasispecies (more details in section 1.11), ultra-deep high throughput next generation sequencing (NGS) is the option of choice for HIV-1 drug resistance genotyping. Ultra-deep high throughput NGS allows for the sequencing of multiple samples with the addition of a sample specific tag sequence for each sample, which enables low cost drug resistant genotyping per sample (Dudley et al., 2012). However, ultra-deep sequencing has limitations that need to be considered before data analysis.

A PCR amplification step precedes the ultra-deep sequencing in all NGS systems discussed in section 1.11. The PCR amplification step has embedded errors like DNA recombination (Kanagawa, 2003; Meyerhans et al., 1990; Yang et al., 1996), DNA synthesis errors (Hughes and Totten, 2003; Mansky and Temin, 1995) and DNA re-sampling errors (Liu et al., 1996). Furthermore, the actual sequencing step also generates errors that can be either insertions/deletions (indels) or substitution errors, depending on a NGS system. For more details, see section 1.11. These errors add artificial variation in the HIV-1 population, confounding the real ones. A new technology has been introduced that enables tagging every viral sequence with a specific sequence (called PrimerID) before the PCR and sequencing step (Jabara et al., 2011). The technology enables tracking of every sequence originating from a template viral sequence, which can then be used to generate a consensus sequence that represents the original viral sequence (Jabara et al., 2011).

A quality score is attached to all the bases in sequence reads, which indicates a probability that the base call is incorrect. Poor quality bases might compromise the downstream data analysis. Quality trimming tools are used to trim out poor quality bases to ensure only high quality bases are analyzed to generate high quality result.

With the limitations in all the NGS systems, Roche/454 is widely used for HIV-1 drug resistance genotyping for its longer read length that enables the characterization of the drug resistant mutation patterns across the genes of the virus. However, the frequency of base call errors has been observed as much as six times in homopolymeric region than non-homopolymeric region (Margulies et al., 2005a; Wang et al., 2007), which needs to be considered as there are specific drug resistant mutations in homopolymer regions (Figure 1.15). PrimerID technology (Jabara et al., 2011) might be widely used in future to correct errors in homopolymer region besides other errors. Strong tools are required for accurate genotyping of sequences from the viral population using the HIV reference sequence. Drug resistance test with accurate genotyping would give accurate drug susceptibility.




Figure 1.15: HIV-1 drug resistant positions at homopolymer regions. Source: Dudley et al 2012 (Dudley et al., 2012)

### 1.12 Thesis Outline

**Chapter 2**: The chapter introduces and describes, in detail, a novel algorithm QTrim for quality trimming of Roche/454 ultra-deep high throughput sequence data. QTrim is optimized for both poor and high quality data. HIV-1 resistance test requires high quality genotypic data and QTrim is designed to quality control the data for the test. QTrim is compared to other widely used quality trimming tools and the comparative analysis result is also presented. The entire chapter is produced as a paper for publication entitled “**QTrim: A novel tool for the quality trimming of sequence reads generated using the Roche/454 sequencing platform” (Shrestha, RK and Travers, Simon; being reviewed)**.

**Chapter 3**: The chapter introduces Primer ID technique recently developed to correct ultra-deep sequencing errors. The chapter also discusses a comparative analysis of sequence data with and without Primer ID approach and the impact of the technology on downstream analysis. The Primer ID approach sequence data is obtained from a study conducted to observe HIV virus response on the vaccine. The study was conducted in the University of Cape Town.

**Chapter 4**: The chapter introduces and describes the computational pipeline called Seq2Res that facilitates low cost HIV drug resistance test. The chapter describes a workflow of the pipeline, the requirements of the pipeline, HIV drug resistance output files and plots that summaries overall analysis. The test data is obtained from a study called CIPRA-SA, which is a trial of antiretroviral drug monitoring strategy in resource poor setting. The chapter is included in paper publication.

**Chapter 5**: This chapter discusses on comparison of clinical data and sequence data analyzed using Seq2Res pipeline. Excitingly, the sequence data analyzed using Seq2Res agrees to clinical data.

**Bibliography**

Ammaranond, P, Sanguansittianan, S (2012) Mechanism of HIV antiretroviral drugs progress toward drug resistance. *Fundamental & Clinical Pharmacology* **26**: 146–161.

Apetrei, C, Robertson, DL, Marx, PA (2004) The history of SIVS and AIDS: epidemiology, phylogeny and biology of isolates from naturally SIV infected non-human primates (NHP) in Africa. *Frontiers in bioscience: a journal and virtual library* **9**: 225-254.

Ariën, KK, Abraha, A, Quiñones-Mateu, ME, Kestens, L, Vanham, G, Arts, EJ (2005) The Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 (HIV-1) Group M, HIV-1 Group O, and HIV-2 Isolates. *Journal of Virology* **79**: 8979-8990.

Artenstein, AW, Coppola, J, Brown, AE, Carr, JK, Sanders-Buell, E, Galbarini, E, Mascola, JR, VanCott, TC, Schonbrood, P, McCutchan, FE, et al. (1995) Multiple introductions of HIV-1 subtype E into the western hemisphere. *Lancet* **346**: 1197-1198.

Ayouba, A, Souquieres, S, Njinku, B, Martin, PM, Muller-Trutwin, MC, Roques, P, Barre-Sinoussi, F, Mauclere, P, Simon, F, Nerrienet, E (2000) HIV-1 group N among HIV-1-seropositive individuals in Cameroon. *AIDS* **14**: 2623-2625.

Bailes, E, Chaudhuri, RR, Santiago, ML, Bibollet-Ruche, F, Hahn, BH, Sharp, PM (2002) The Evolution of Primate Lentiviruses and the Origins of AIDS. In: The Molecular Epidemiology of Human Viruses, Springer US, pp. 65-96.

Baldwin, CE, Sanders, RW, Berkhout, B (2003) Inhibiting HIV-1 entry with fusion inhibitors. *Curr Med Chem* **10**: 1633-1642.

Baltimore, D (1971) Expression of animal virus genomes. *Bacteriological Reviews* **35**: 235.

Balzarini, J (2004) Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1. *Current Topics in Medicinal Chemistry* **4**: 921-944.

Bangsberg, DR, Kroetz, DL, Deeks, SG (2007) Adherence-resistance relationships to combination HIV antiretroviral therapy. *Curr HIV/AIDS Rep* **4**: 65-72.

Baur, AS, Sawai, ET, Dazin, P, Fantl, WJ, Cheng-Mayer, C, Peterlin, BM (1994) HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. *Immunity* **1**: 373-384.

Baxter, JD, Mayers, DL, Wentworth, DN, Neaton, JD, Hoover, ML, Winters, MA, Mannheimer, SB, Thompson, MA, Abrams, DI, Brizz, BJ, Ioannidis, JP, Merigan, TC (2000) A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. *AIDS* **14**: F83-93.

Bebenek, K, Abbotts, J, Roberts, JD, Wilson, SH, Kunkel, TA (1989) Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. *J Biol Chem* **264**: 16948-16956.

Bebenek, K, Abbotts, J, Wilson, SH, Kunkel, TA (1993) Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. *J Biol Chem* **268**: 10324-10334.

Ben-Artzi, H, Shemesh, J, Zeelon, E, Amit, B, Kleiman, L, Gorecki, M, Panet, A (1996) Molecular analysis of the second template switch during reverse transcription of the HIV RNA template. *Biochemistry* **35**: 10549-10557.

Bentley, DR, Balasubramanian, S, Swerdlow, HP, Smith, GP, Milton, J, Brown, CG, Hall, KP, Evers, DJ, Barnes, CL, Bignell, HR, Boutell, JM, Bryant, J, Carter, RJ, Keira Cheetham, R, Cox, AJ, Ellis, DJ, Flatbush, MR, Gormley, NA, Humphray, SJ, Irving, LJ, Karbelashvili, MS, Kirk, SM, Li, H, Liu, X, Maisinger, KS, Murray, LJ, Obradovic, B, Ost, T, Parkinson, ML, Pratt, MR, Rasolonjatovo, IM, Reed, MT, Rigatti, R, Rodighiero, C, Ross, MT, Sabot, A, Sankar, SV, Scally, A, Schroth, GP, Smith, ME, Smith, VP, Spiridou, A, Torrance, PE, Tzonev, SS, Vermaas, EH, Walter, K, Wu, X, Zhang, L, Alam, MD, Anastasi, C, Aniebo, IC, Bailey, DM, Bancarz, IR, Banerjee, S, Barbour, SG, Baybayan, PA, Benoit, VA, Benson, KF, Bevis, C, Black, PJ, Boodhun, A, Brennan, JS, Bridgham, JA, Brown, RC, Brown, AA, Buermann, DH, Bundu, AA, Burrows, JC, Carter, NP, Castillo, N, Chiara, ECM, Chang, S, Neil Cooley, R, Crake, NR, Dada, OO, Diakoumakos, KD, Dominguez-Fernandez, B, Earnshaw, DJ, Egbujor, UC, Elmore, DW, Etchin, SS, Ewan, MR, Fedurco, M, Fraser, LJ, Fuentes Fajardo, KV, Scott Furey, W, George, D, Gietzen, KJ, Goddard, CP, Golda, GS, Granieri, PA, Green, DE, Gustafson, DL, Hansen, NF, Harnish, K, Haudenschild, CD, Heyer, NI, Hims, MM, Ho, JT, Horgan, AM, Hoschler, K, Hurwitz, S, Ivanov, DV, Johnson, MQ, James, T, Huw Jones, TA, Kang, GD, Kerelska, TH, Kersey, AD, Khrebtukova, I, Kindwall, AP, Kingsbury, Z, Kokko-Gonzales, PI, Kumar, A, Laurent, MA, Lawley, CT, Lee, SE, Lee, X, Liao, AK, Loch, JA, Lok, M, Luo, S, Mammen, RM, Martin, JW, McCauley, PG, McNitt, P, Mehta, P, Moon, KW, Mullens, JW, Newington, T, Ning, Z, Ling Ng, B, Novo, SM, O'Neill, MJ, Osborne, MA, Osnowski, A, Ostadan, O, Paraschos, LL, Pickering, L, Pike, AC, Chris Pinkard, D, Pliskin, DP, Podhasky, J, Quijano, VJ, Raczy, C, Rae, VH, Rawlings, SR, Chiva Rodriguez, A, Roe, PM, Rogers, J, Rogert Bacigalupo, MC, Romanov, N, Romieu, A, Roth, RK, Rourke, NJ, Ruediger, ST, Rusman, E, Sanches-Kuiper, RM, Schenker, MR, Seoane, JM, Shaw, RJ, Shiver, MK, Short, SW, Sizto, NL, Sluis, JP, Smith, MA, Ernest Sohna Sohna, J, Spence, EJ, Stevens, K, Sutton, N, Szajkowski, L, Tregidgo, CL, Turcatti, G, Vandevondele, S, Verhovsky, Y, Virk, SM, Wakelin, S, Walcott, GC, Wang, J, Worsley, GJ, Yan, J, Yau, L, Zuerlein, M, Mullikin, JC, Hurles, ME, McCooke, NJ, West, JS, Oaks, FL, Lundberg, PL, Klenerman, D, Durbin, R, Smith, AJ (2008) Accurate whole human genome sequencing using reversible terminator chemistry. *Nature* **456**: 53-59.

Blagoveshchenskaya, AD, Thomas, L, Feliciangeli, SF, Hung, CH, Thomas, G (2002) HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. *Cell* **111**: 853-866.

Borrow, P, Lewicki, H, Wei, X, Horwitz, MS, Peffer, N, Meyers, H, Nelson, JA, Gairin, JE, Hahn, BH, Oldstone, MB, Shaw, GM (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat Med* **3**: 205-211.

Borsetti, A, Ohagen, A, Gottlinger, HG (1998) The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. *J Virol* **72**: 9313-9317.

Bourgeois, CF, Kim, YK, Churcher, MJ, West, MJ, Karn, J (2002) Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences. *Mol Cell Biol* **22**: 1079-1093.

Briggs, JA, Krausslich, HG The molecular architecture of HIV. *J Mol Biol* **410**: 491-500.

Briggs, JA, Simon, MN, Gross, I, Krausslich, HG, Fuller, SD, Vogt, VM, Johnson, MC (2004) The stoichiometry of Gag protein in HIV-1. *Nat Struct Mol Biol* **11**: 672-675.

Briz, V, Poveda, E, Soriano, V (2006) HIV entry inhibitors: mechanisms of action and resistance pathways. *Journal of Antimicrobial Chemotherapy* **57**: 619-627.

Bukrinsky, MI, Sharova, N, Dempsey, MP, Stanwick, TL, Bukrinskaya, AG, Haggerty, S, Stevenson, M (1992) Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. *Proceedings of the National Academy of Sciences* **89**: 6580-6584.

Bukrinsky, MI, Sharova, N, McDonald, TL, Pushkarskaya, T, Tarpley, WG, Stevenson, M (1993) Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. *Proc Natl Acad Sci U S A* **90**: 6125-6129.

Cameron, W, Japour, AJ, Xu, Y, Hsu, A, Mellors, J, Farthing, C, Cohen, C, Poretz, D, Markowitz, M, Follansbee, S (1999) Ritonavir and saquinavir combination therapy for the treatment of HIV infection. *AIDS* **13**: 213-224.

Carpenter, CC, Fischl, MA, Hammer, SM, Hirsch, MS, Jacobsen, DM, Katzenstein, DA, Montaner, JS, Richman, DD, Saag, MS, Schooley, RT (1997) Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. *JAMA, the journal of the American Medical Association* **277**: 1962-1969.

Carr, A, Miller, J, Law, M, Cooper, DA (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. *AIDS* **14**: F25-32.

Carr, A, Samaras, K, Burton, S, Law, M, Freund, J, Chisholm, DJ, Cooper, DA (1998a) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. *AIDS* **12**: F51-58.

Carr, A, Samaras, K, Chisholm, DJ, Cooper, DA (1998b) Abnormal fat distribution and use of protease inhibitors. *Lancet* **351**: 1736.

Carr, A, Samaras, K, Chisholm, DJ, Cooper, DA (1998c) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. *Lancet* **351**: 1881-1883.

Casado, JL, Hertogs, K, Ruiz, L, Dronda, F, Van Cauwenberge, A, Arno, A, Garcia-Arata, I, Bloor, S, Bonjoch, A, Blazquez, J, Clotet, B, Larder, B (2000) Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. *AIDS* **14**: F1-7.

Chan, DC, Fass, D, Berger, JM, Kim, PS (1997) Core Structure of gp41 from the HIV Envelope Glycoprotein. *Cell* **89**: 263-273.

Chen, X, Tsiang, M, Yu, F, Hung, M, Jones, GS, Zeynalzadegan, A, Qi, X, Jin, H, Kim, CU, Swaminathan, S, Chen, JM (2008) Modeling, Analysis, and Validation of a Novel HIV Integrase Structure Provide Insights into the Binding Modes of Potent Integrase Inhibitors. *Journal of Molecular Biology* **380**: 504-519.

Cherry, S, Doukas, T, Armknecht, S, Whelan, S, Wang, H, Sarnow, P, Perrimon, N (2005) Genome-wide RNAi screen reveals a specific sensitivity of IRES-containing RNA viruses to host translation inhibition. *Genes Dev* **19**: 445-452.

Chou, S, Upton, H, Bao, K, Schulze-Gahmen, U, Samelson, AJ, He, N, Nowak, A, Lu, H, Krogan, NJ, Zhou, Q, Alber, T HIV-1 Tat recruits transcription elongation factors dispersed along a flexible AFF4 scaffold. *Proc Natl Acad Sci U S A* **110**: E123-131.

Christ, F, Thys, W, De Rijck, J, Gijsbers, R, Albanese, A, Arosio, D, Emiliani, S, Rain, JC, Benarous, R, Cereseto, A, Debyser, Z (2008) Transportin-SR2 imports HIV into the nucleus. *Curr Biol* **18**: 1192-1202.

Chukkapalli, V, Oh, SJ, Ono, A Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. *Proc Natl Acad Sci U S A* **107**: 1600-1605.

Clavel, F, Hance, AJ (2004) HIV Drug Resistance. *New England Journal of Medicine* **350**: 1023-1035.

Cohen, EA, Subbramanian, RA, Gottlinger, HG (1996) Role of auxiliary proteins in retroviral morphogenesis. *Curr Top Microbiol Immunol* **214**: 219-235.

Cohen, EA, Terwilliger, EF, Sodroski, JG, Haseltine, WA (1988) Identification of a protein encoded by the vpu gene of HIV-1. *Nature* **334**: 532-534.

Collier, AC, Coombs, RW, Fischl, MA, Skolnik, PR, Northfelt, D, Boutin, P, Hooper, CJ, Kaplan, LD, Volberding, PA, Davis, LG, Henrard, DR, Weller, S, Corey, L (1993) Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. *Ann Intern Med* **119**: 786-793.

Collier, AC, Coombs, RW, Schoenfeld, DA, Bassett, RL, Timpone, J, Baruch, A, Jones, M, Facey, K, Whitacre, C, McAuliffe, VJ, Friedman, HM, Merigan, TC, Reichman, RC, Hooper, C, Corey, L (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. *N Engl J Med* **334**: 1011-1017.

Condra, JH, Schleif, WA, Blahy, OM, Gabryelski, LJ, Graham, DJ, Quintero, JC, Rhodes, A, Robbins, HL, Roth, E, Shivaprakash, M, et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. *Nature* **374**: 569-571.

Connor, EM, Sperling, RS, Gelber, R, Kiselev, P, Scott, G, O'Sullivan, MJ, VanDyke, R, Bey, M, Shearer, W, Jacobson, RL (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *New England Journal of Medicine* **331**: 1173-1180.

Connor, RI, Chen, BK, Choe, S, Landau, NR (1995) Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes. *Virology* **206**: 935-944.

Corbitt, G, Bailey, A, Williams, G (1990) HIV infection in Manchester, 1959. *The Lancet* **336**: 51.

Cullen, BR (1991) Regulation of HIV-1 gene expression. *FASEB J* **5**: 2361-2368.

D'Aquila, RT, Johnson, VA, Welles, SL, Japour, AJ, Kuritzkes, DR, DeGruttola, V, Reichelderfer, PS, Coombs, RW, Crumpacker, CS, Kahn, JO, Richman, DD (1995) Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. *Ann Intern Med* **122**: 401-408.

Daly, TJ, Cook, KS, Gray, GS, Maione, TE, Rusche, JR (1989) Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. *Nature* **342**: 816-819.

Damond, F, Worobey, M, Campa, P, Farfara, I, Colin, G, Matheron, S, Brun-Vézinet, Ft, Robertson, DL, Simon, Ft (2004) Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. *AIDS research and human retroviruses* **20**: 666–672.

Darke, PL, Nutt, RF, Brady, SF, Garsky, VM, Ciccarone, TM, Leu, C-T, Lumma, PK, Freidinger, RM, Veber, DF, Sigal, IS (1988) HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. *Biochemical and Biophysical Research Communications* **156**: 297-303.

Davey, NE, Travé, G, Gibson, TJ (2011) How viruses hijack cell regulation. *Trends in Biochemical Sciences* **36**: 159-169.

Davies, JF, Hostomska, Z, Hostomsky, Z, Jordan, Matthews, DA (1991) Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. *Science* **252**: 88-95.

Dawson, L, Yu, X-F (1998) The Role of Nucleocapsid of HIV-1 in Virus Assembly. *Virology* **251**: 141-157.

De Clercq, E (2002) Strategies in the design of antiviral drugs. *Nature Reviews Drug Discovery* **1**: 13-25.

Decroly, E, Vandenbranden, M, Ruysschaert, JM, Cogniaux, J, Jacob, GS, Howard, SC, Marshall, G, Kompelli, A, Basak, A, Jean, F (1994) The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). *Journal of Biological Chemistry* **269**: 12240-12247.

Delwart, E, Magierowska, M, Royz, M, Foley, B, Peddada, L, Smith, R, Heldebrant, C, Conrad, A, Busch, M (2002) Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. *AIDS* **16**: 189-195.

Demirov, DG, Orenstein, JM, Freed, EO (2002) The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. *J Virol* **76**: 105-117.

di Marzo Veronese, F, Reitz, MS, Jr., Gupta, G, Robert-Guroff, M, Boyer-Thompson, C, Louie, A, Gallo, RC, Lusso, P (1993) Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. *J Biol Chem* **268**: 25894-25901.

Dismuke, DJ, Aiken, C (2006) Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. *J Virol* **80**: 3712-3720.

Dong, X, Li, H, Derdowski, A, Ding, L, Burnett, A, Chen, X, Peters, TR, Dermody, TS, Woodruff, E, Wang, JJ, Spearman, P (2005) AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. *Cell* **120**: 663-674.

Dudley, DM, Chin, EN, Bimber, BN, Sanabani, SS, Tarosso, LF, Costa, PR, Sauer, MM, Kallas, EG, O'Connor, DH (2012) Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. *PLoS One* **7**: e36494.

Duffalo, ML, James, CW (2003) Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection. *The Annals of Pharmacotherapy* **37**: 1448-1456.

Dumonceaux, J, Nisole, S, Chanel, C, Quivet, L, Amara, A, Baleux, F, Briand, P, Hazan, U (1998) Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. *J Virol* **72**: 512-519.

Durant, J, Clevenbergh, P, Halfon, P, Delgiudice, P, Porsin, S, Simonet, P, Montagne, N, Boucher, CA, Schapiro, JM, Dellamonica, P (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. *Lancet* **353**: 2195-2199.

Dwyer, JJ, Hasan, A, Wilson, KL, White, JM, Matthews, TJ, Delmedico, MK (2003) The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. *Biochemistry* **42**: 4945-4953.

Emiliani, S, Mousnier, A, Busschots, K, Maroun, M, Maele, BV, Tempé, D, Vandekerckhove, L, Moisant, F, Ben-Slama, L, Witvrouw, M, Christ, F, Rain, J-C, Dargemont, C, Debyser, Z, Benarous, R (2005) Integrase Mutants Defective for Interaction with LEDGF/p75 Are Impaired in Chromosome Tethering and HIV-1 Replication. *Journal of Biological Chemistry* **280**: 25517-25523.

Eron, JJ, Benoit, SL, Jemsek, J, MacArthur, RD, Santana, J, Quinn, JB, Kuritzkes, DR, Fallon, MA, Rubin, M (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. *N Engl J Med* **333**: 1662-1669.

Esnouf, R, Ren, J, Ross, C, Jones, Y, Stammers, D, Stuart, D (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. *Nature Structural & Molecular Biology* **2**: 303–308.

Esparza, J, Bhamarapravati, N (2000) Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? *Lancet* **355**: 2061-2066.

Ewing, B, Hillier, L, Wendl, MC, Green, P (1998) Base-calling of automated sequencer traces using phred. I. Accuracy assessment. *Genome Res* **8**: 175-185.

Fang, G, Weiser, B, Kuiken, C, Philpott, SM, Rowland-Jones, S, Plummer, F, Kimani, J, Shi, B, Kaul, R, Bwayo, J, Anzala, O, Burger, H (2004) Recombination following superinfection by HIV-1. *AIDS* **18**: 153-159.

Farnet, CM, Haseltine, WA (1991) Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. *J Virol* **65**: 1910-1915.

Fassati, A, Gorlich, D, Harrison, I, Zaytseva, L, Mingot, JM (2003) Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7. *EMBO J* **22**: 3675-3685.

Fätkenheuer, G, Pozniak, AL, Johnson, MA, Plettenberg, A, Staszewski, S, Hoepelman, AIM, Saag, MS, Goebel, FD, Rockstroh, JK, Dezube, BJ, Jenkins, TM, Medhurst, C, Sullivan, JF, Ridgway, C, Abel, S, James, IT, Youle, M, van der Ryst, E (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. *Nature Medicine* **11**: 1170-1172.

Fischer, W, Ganusov, VV, Giorgi, EE, Hraber, PT, Keele, BF, Leitner, T, Han, CS, Gleasner, CD, Green, L, Lo, CC, Nag, A, Wallstrom, TC, Wang, S, McMichael, AJ, Haynes, BF, Hahn, BH, Perelson, AS, Borrow, P, Shaw, GM, Bhattacharya, T, Korber, BT (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. *PLoS One* **5**: e12303.

Fischl, MA, Olson, RM, Follansbee, SE, Lalezari, JP, Henry, DH, Frame, PT, Remick, SC, Salgo, MP, Lin, AH, Nauss-Karol, C, Lieberman, J, Soo, W (1993) Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. *Ann Intern Med* **118**: 762-769.

Fischl, MA, Richman, DD, Hansen, N, Collier, AC, Carey, JT, Para, MF, Hardy, WD, Dolin, R, Powderly, WG, Allan, JD, et al. (1990) The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. *Ann Intern Med* **112**: 727-737.

Fouchier, RA, Groenink, M, Kootstra, NA, Tersmette, M, Huisman, HG, Miedema, F, Schuitemaker, H (1992) Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. *J Virol* **66**: 3183-3187.

Francis, DP, Curran, JW, Essex, M (1983) Epidemic acquired immune deficiency syndrome: epidemiologic evidence for a transmissible agent. *Journal of the National Cancer Institute* **71**: 5–9.

Frankel, AD, Young, JAT (1998) HIV-1: Fifteen Proteins and an RNA. *Annual Review of Biochemistry* **67**: 1-25.

Friedman-Kien, AE (1981) Disseminated Kaposi's sarcoma syndrome in young homosexual men. *Journal of the American Academy of Dermatology* **5**: 468–471.

Friedman-Kien, AE, Laubenstein, L, Marmor, M, Hymes, K, Green, J, Ragaz, A, Gottleib, J, Muggia, F, Demopoulos, R, Weintraub, M (1981) Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. *MMWR* **30**: 305–308.

Furuta, RA, Wild, CT, Weng, Y, Weiss, CD (1998) Capture of an early fusion-active conformation of HIV-1 gp41. *Nature Structural & Molecular Biology* **5**: 276-279.

Gallo, RC, Sarin, PS, Gelmann, EP, Robert-Guroff, M, Richardson, E, Kalyanaraman, VS, Mann, D, Sidhu, GD, Stahl, RE, Zolla-Pazner, S, Leibowitch, J, Popovic, M (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). *Science (New York, NY)* **220**: 865-867.

Ganser-Pornillos, BK, von Schwedler, UK, Stray, KM, Aiken, C, Sundquist, WI (2004) Assembly properties of the human immunodeficiency virus type 1 CA protein. *J Virol* **78**: 2545-2552.

Gao, F, Bailes, E, Robertson, DL, Chen, Y, Rodenburg, CM, Michael, SF, Cummins, LB, Arthur, LO, Peeters, M, Shaw, GM (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. *Nature* **397**: 436-441.

Gao, F, Vidal, N, Li, Y, Trask, SA, Chen, Y, Kostrikis, LG, Ho, DD, Kim, J, Oh, M-D, Choe, K, Salminen, M, Robertson, DL, Shaw, GM, Hahn, BH, Peeters, M (2001) Evidence of Two Distinct Subsubtypes within the HIV-1 Subtype A Radiation. *AIDS Research and Human Retroviruses* **17**: 675-688.

Gao, F, Yue, L, Robertson, DL, Hill, SC, Hui, H, Biggar, RJ, Neequaye, AE, Whelan, TM, Ho, DD, Shaw, GM (1994) Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. *Journal of virology* **68**: 7433–7447.

Gao, F, Yue, L, White, AT, Pappas, PG, Barchue, J, Hanson, AP, Greene, BM, Sharp, PM, Shaw, GM, Hahn, BH (1992) Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. *Nature* **358**: 495-499.

Garcia, JV, Miller, AD (1991) Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. *Nature* **350**: 508–511.

Gaynor, R (1992) Cellular transcription factors involved in the regulation of HIV-1 gene expression. *AIDS* **6**: 347-363.

Glenn, TC (2011) Field guide to next-generation DNA sequencers. *Mol Ecol Resour* **11**: 759-769.

Goodenow, M, Huet, T, Saurin, W, Kwok, S, Sninsky, J, Wain-Hobson, S (1989) HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. *J Acquir Immune Defic Syndr* **2**: 344-352.

Gottlieb, MS, Schroff, R, Schanker, HM, Weisman, JD, Fan, PT, Wolf, RA, Saxon, A (1981) \textitPneumocystis carinii Pneumonia and Mucosal Candidiasis in Previously Healthy Homosexual Men. *New England Journal of Medicine* **305**: 1425-1431.

Göttlinger, HG, Sodroski, JG, Haseltine, WA (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. *Proceedings of the National Academy of Sciences* **86**: 5781-5785.

Greenberg, ME, Iafrate, AJ, Skowronski, J (1998) The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. *EMBO J* **17**: 2777-2789.

Gu, Z, Gao, Q, Faust, EA, Wainberg, MA (1995) Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. *J Gen Virol* **76 ( Pt 10)**: 2601-2605.

Gulick, RM, Mellors, JW, Havlir, D, Eron, JJ, Gonzalez, C, McMahon, D, Jonas, L, Meibohm, A, Holder, D, Schleif, WA, Condra, JH, Emini, EA, Isaacs, R, Chodakewitz, JA, Richman, DD (1998) Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. *JAMA* **280**: 35-41.

Gulick, RM, Mellors, JW, Havlir, D, Eron, JJ, Gonzalez, C, McMahon, D, Richman, DD, Valentine, FT, Jonas, L, Meibohm, A, Emini, EA, Chodakewitz, JA, Deutsch, P, Holder, D, Schleif, WA, Condra, JH (1997) Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. *New England Journal of Medicine* **337**: 734-739.

Gulick, RM, Mellors, JW, Havlir, D, Eron, JJ, Meibohm, A, Condra, JH, Valentine, FT, McMahon, D, Gonzalez, C, Jonas, L (2000) 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. *Annals of internal medicine* **133**: 35-39.

Gürtler, L (2004) [Zoonotic infections stimulation]. *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz* **47**: 609-610.

Haase, AT Targeting early infection to prevent HIV-1 mucosal transmission. *Nature* **464**: 217-223.

Hahn, BH, Shaw, GM, De, KM, Sharp, PM (2000) AIDS as a zoonosis: scientific and public health implications. *Science* **287**: 607–614.

Hammer, SM, Eron, JJ, Jr., Reiss, P, Schooley, RT, Thompson, MA, Walmsley, S, Cahn, P, Fischl, MA, Gatell, JM, Hirsch, MS, Jacobsen, DM, Montaner, JS, Richman, DD, Yeni, PG, Volberding, PA (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. *JAMA* **300**: 555-570.

Hammer, SM, Katzenstein, DA, Hughes, MD, Gundacker, H, Schooley, RT, Haubrich, RH, Henry, WK, Lederman, MM, Phair, JP, Niu, M, Hirsch, MS, Merigan, TC (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. *N Engl J Med* **335**: 1081-1090.

Hammer, SM, Squires, KE, Hughes, MD, Grimes, JM, Demeter, LM, Currier, JS, Eron, JJ, Feinberg, JE, Balfour, HH, Deyton, LR, Chodakewitz, JA, Fischl, MA, Phair, JP, Pedneault, L, Nguyen, B-Y, Cook, JC (1997) A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. *New England Journal of Medicine* **337**: 725-733.

Hanna, GJ, D'Aquila, RT (2001) Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. *Clin Infect Dis* **32**: 774-782.

Hanna, GJ, Johnson, VA, Kuritzkes, DR, Richman, DD, Brown, AJ, Savara, AV, Hazelwood, JD, D'Aquila, RT (2000) Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. *J Infect Dis* **181**: 904-911.

Havlir, DV, Marschner, IC, Hirsch, MS, Collier, AC, Tebas, P, Bassett, RL, Ioannidis, JP, Holohan, MK, Leavitt, R, Boone, G, Richman, DD (1998) Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. *N Engl J Med* **339**: 1261-1268.

Hazuda, DJ, Anthony, NJ, Gomez, RP, Jolly, SM, Wai, JS, Zhuang, L, Fisher, TE, Embrey, M, Guare, JP, Egbertson, MS, Vacca, JP, Huff, JR, Felock, PJ, Witmer, MV, Stillmock, KA, Danovich, R, Grobler, J, Miller, MD, Espeseth, AS, Jin, L, Chen, I-W, Lin, JH, Kassahun, K, Ellis, JD, Wong, BK, Xu, W, Pearson, PG, Schleif, WA, Cortese, R, Emini, E, Summa, V, Holloway, MK, Young, SD (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. *Proceedings of the National Academy of Sciences of the United States of America* **101**: 11233-11238.

He, J, Choe, S, Walker, R, Marzio, PD, Morgan, DO, Landau, NR (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *Journal of Virology* **69**: 6705-6711.

He, N, Zhou, Q New insights into the control of HIV-1 transcription: when Tat meets the 7SK snRNP and super elongation complex (SEC). *J Neuroimmune Pharmacol* **6**: 260-268.

Hemelaar, J, Gouws, E, Ghys, PD, Osmanov, S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. *AIDS* **20**: W13-W23.

Hertogs, K, de Bethune, MP, Miller, V, Ivens, T, Schel, P, Van Cauwenberge, A, Van Den Eynde, C, Van Gerwen, V, Azijn, H, Van Houtte, M, Peeters, F, Staszewski, S, Conant, M, Bloor, S, Kemp, S, Larder, B, Pauwels, R (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. *Antimicrob Agents Chemother* **42**: 269-276.

Himmel, DM, Sarafianos, SG, Dharmasena, S, Hossain, MM, McCoy-Simandle, K, Ilina, T, Clark, AD, Jr., Knight, JL, Julias, JG, Clark, PK, Krogh-Jespersen, K, Levy, RM, Hughes, SH, Parniak, MA, Arnold, E (2006) HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. *ACS Chem Biol* **1**: 702-712.

Hirsch MS, B-VF (2000) Antiretroviral drug resistance testing in adult hiv-1 infection: Recommendations of an international aids society–usa panel. *JAMA* **283**: 2417-2426.

Hirsch, VM, Olmsted, RA, Murphey-Corb, M, Purcell, RH, Johnson, PR (1989) An African primate lentivirus (SIVsmclosely related to HIV-2.

Ho, DD, Bieniasz, PD (2008) HIV-1 at 25. *Cell* **133**: 561-565.

Ho, DD, Neumann, AU, Perelson, AS, Chen, W, Leonard, JM, Markowitz, M (1995a) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature* **373**: 123-126.

Ho, DD, Neumann, AU, Perelson, AS, Chen, W, Leonard, JM, Markowitz, M (1995b) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature* **373**: 123–126.

Huang, C-c, Lam, SN, Acharya, P, Tang, M, Xiang, S-H, Hussan, SS-u, Stanfield, RL, Robinson, J, Sodroski, J, Wilson, IA, Wyatt, R, Bewley, CA, Kwong, PD (2007) Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4. *Science* **317**: 1930-1934.

Huet, T, Cheynier, R, Meyerhans, A, Roelants, G, Wain-Hobson, S (1990) Genetic organization of a chimpanzee lentivirus related to HIV-1.

Hughes, JP, Totten, P (2003) Estimating the accuracy of polymerase chain reaction-based tests using endpoint dilution. *Biometrics* **59**: 505-511.

Hulme, AE, Perez, O, Hope, TJ (2011) Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. *Proc Natl Acad Sci U S A* **108**: 9975-9980.

Hussain, A, Wesley, C, Khalid, M, Chaudhry, A, Jameel, S (2008) Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. *Journal of virology* **82**: 893–902.

Ilina, T, Parniak, MA (2008) Inhibitors of HIV‐1 Reverse Transcriptase. In: Advances in Pharmacology, Academic Press, pp. 121-167.

Jabara, CB, Jones, CD, Roach, J, Anderson, JA, Swanstrom, R (2011) Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. *Proc Natl Acad Sci U S A* **108**: 20166-20171.

Jacks, T, Power, MD, Masiarz, FR, Luciw, PA, Barr, PJ, Varmus, HE (1988) Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. *Nature* **331**: 280-283.

Jacobo-Molina, A, Arnold, E (1991) HIV reverse transcriptase structure-function relationships. *Biochemistry* **30**: 6351–6361.

Jager, S, Kim, DY, Hultquist, JF, Shindo, K, LaRue, RS, Kwon, E, Li, M, Anderson, BD, Yen, L, Stanley, D, Mahon, C, Kane, J, Franks-Skiba, K, Cimermancic, P, Burlingame, A, Sali, A, Craik, CS, Harris, RS, Gross, JD, Krogan, NJ Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. *Nature* **481**: 371-375.

Jakobson, CG, Dinnar, U, Feinsod, M, Nemirovsky, Y (2002) Ion-sensitive field-effect transistors in standard CMOS fabricated by post processing. *IEEE Sensors Journal* **2**: 279-287.

Japour, AJ, Welles, S, D'Aquila, RT, Johnson, VA, Richman, DD, Coombs, RW, Reichelderfer, PS, Kahn, JO, Crumpacker, CS, Kuritzkes, DR (1995) Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. *J Infect Dis* **171**: 1172-1179.

Ji, H, Li, Y, Graham, M, Liang, BB, Pilon, R, Tyson, S, Peters, G, Tyler, S, Merks, H, Bertagnolio, S, Soto-Ramirez, L, Sandstrom, P, Brooks, J (2011) Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance. *Antivir Ther* **16**: 871-878.

Johnson, JA, Geretti, AM (2010) Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. *J Antimicrob Chemother* **65**: 1322-1326.

Johnson, VA, Calvez, V, Gunthard, HF, Paredes, R, Pillay, D, Shafer, RW, Wensing, AM, Richman, DD (2013) Update of the drug resistance mutations in HIV-1: March 2013. *Top Antivir Med* **21**: 6-14.

Jowett, JB, Planelles, V, Poon, B, Shah, NP, Chen, M-L, Chen, IS (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2+ M phase of the cell cycle. *Journal of virology* **69**: 6304–6313.

Kahn, JO, Lagakos, SW, Richman, DD, Cross, A, Pettinelli, C, Liou, SH, Brown, M, Volberding, PA, Crumpacker, CS, Beall, G, et al. (1992) A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. *N Engl J Med* **327**: 581-587.

Kanagawa, T (2003) Bias and artifacts in multitemplate polymerase chain reactions (PCR). *J Biosci Bioeng* **96**: 317-323.

Karacostas, V, Wolffe, EJ, Nagashima, K, Gonda, MA, Moss, B (1993) Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. *Virology* **193**: 661–671.

Karn, J, Stoltzfus, CM Transcriptional and posttranscriptional regulation of HIV-1 gene expression. *Cold Spring Harbor Perspectives in Medicine* **2**.

Keele, BF, Giorgi, EE, Salazar-Gonzalez, JF, Decker, JM, Pham, KT, Salazar, MG, Sun, C, Grayson, T, Wang, S, Li, H, Wei, X, Jiang, C, Kirchherr, JL, Gao, F, Anderson, JA, Ping, LH, Swanstrom, R, Tomaras, GD, Blattner, WA, Goepfert, PA, Kilby, JM, Saag, MS, Delwart, EL, Busch, MP, Cohen, MS, Montefiori, DC, Haynes, BF, Gaschen, B, Athreya, GS, Lee, HY, Wood, N, Seoighe, C, Perelson, AS, Bhattacharya, T, Korber, BT, Hahn, BH, Shaw, GM (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A* **105**: 7552-7557.

Kellam, P, Boucher, CA, Tijnagel, JM, Larder, BA (1994) Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. *J Gen Virol* **75 ( Pt 2)**: 341-351.

Kellam, P, Larder, BA (1994) Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. *Antimicrob Agents Chemother* **38**: 23-30.

Kliger, Y, Aharoni, A, Rapaport, D, Jones, P, Blumenthal, R, Shai, Y (1997) Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study. *J Biol Chem* **272**: 13496-13505.

Klimkait, T, Strebel, K, Hoggan, MD, Martin, MA, Orenstein, JM (1990) The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. *Journal of Virology* **64**: 621-629.

Koch, MA, Volberding, PA, Lagakos, SW, Booth, DK, Pettinelli, C, Myers, MW (1992) Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. *Arch Intern Med* **152**: 2286-2292.

Korber, B, Gaschen, B, Yusim, K, Thakallapally, R, Kesmir, C, Detours, V (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. *British Medical Bulletin* **58**: 19-42.

Korber, B, Muldoon, M, Theiler, J, Gao, F, Gupta, R, Lapedes, A, Hahn, BH, Wolinsky, S, Bhattacharya, T (2000) Timing the ancestor of the HIV-1 pandemic strains. *Science* **288**: 1789-1796.

Kostrikis, LG, Touloumi, G, Karanicolas, R, Pantazis, N, Anastassopoulou, C, Karafoulidou, A, Goedert, JJ, Hatzakis, A (2002) Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. *J Virol* **76**: 10099-10108.

Kozal, MJ, Shah, N, Shen, N, Yang, R, Fucini, R, Merigan, TC, Richman, DD, Morris, D, Hubbell, E, Chee, M, Gingeras, TR (1996) Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. *Nat Med* **2**: 753-759.

Kuritzkes, DR, Marschner, I, Johnson, VA, Bassett, R, Eron, JJ, Fischl, MA, Murphy, RL, Fife, K, Maenza, J, Rosandich, ME (1999) Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. *AIDS* **13**: 685-694.

LaFemina, RL, Schneider, CL, Robbins, HL, Callahan, PL, LeGrow, K, Roth, E, Schleif, WA, Emini, EA (1992) Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. *Journal of Virology* **66**: 7414-7419.

Laguette, N, Benichou, S, Basmaciogullari, S (2009) Human Immunodeficiency Virus Type 1 Nef Incorporation into Virions Does Not Increase Infectivity. *Journal of Virology* **83**: 1093-1104.

Lama, J, Mangasarian, A, Trono, D (1999) Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. *Current biology: CB* **9**: 622-631.

Larder, B, De Vroey, V, Dehertogh, P (1999) Abstracts of the 3d International Workshop on HIV Drug Resistance and Treatment Strategies (San Diego). London: International Medical Press; 1999. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database [abstract 59]. 41-42.

Larder, BA, Darby, G, Richman, DD (1989a) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. *Science* **243**: 1731-1734.

Larder, BA, Darby, G, Richman, DD (1989b) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. *Science* **243**: 1731-1734.

Larder, BA, Kellam, P, Kemp, SD (1991) Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. *AIDS* **5**: 137-144.

Larder, BA, Kemp, SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). *Science* **246**: 1155-1158.

Larsen, LS, Beliakova-Bethell, N, Bilanchone, V, Zhang, M, Lamsa, A, Dasilva, R, Hatfield, GW, Nagashima, K, Sandmeyer, S (2008) Ty3 nucleocapsid controls localization of particle assembly. *J Virol* **82**: 2501-2514.

Lemey, P, Pybus, OG, Rambaut, A, Drummond, AJ, Robertson, DL, Roques, P, Worobey, M, Vandamme, A-M (2004a) The Molecular Population Genetics of HIV-1 Group O. *Genetics* **167**: 1059-1068.

Lemey, P, Pybus, OG, Rambaut, A, Drummond, AJ, Robertson, DL, Roques, P, Worobey, M, Vandamme, AM (2004b) The molecular population genetics of HIV-1 group O. *Genetics* **167**: 1059-1068.

Lenassi, M, Cagney, G, Liao, M, Vaupotic, T, Bartholomeeusen, K, Cheng, Y, Krogan, NJ, Plemenitas, A, Peterlin, BM HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. *Traffic* **11**: 110-122.

Letvin, NL (2006) Progress and obstacles in the development of an AIDS vaccine. *Nature Reviews Immunology* **6**: 930-939.

Levy, JA, Hoffman, AD, Kramer, SM, Landis, JA, Shimabukuro, JM, Oshiro, LS (1984) Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. *Science* **225**: 840-842.

Lewis, MJ, Lee, P, Ng, HL, Yang, OO (2012) Immune Selection In Vitro Reveals Human Immunodeficiency Virus Type 1 Nef Sequence Motifs Important for Its Immune Evasion Function In Vivo. *Journal of Virology* **86**: 7126-7135.

Liang, J-S, Distler, O, Cooper, DA, Jamil, H, Deckelbaum, RJ, Ginsberg, HN, Sturley, SL (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. *Nature Medicine* **7**: 1327-1331.

Liu, J, Bartesaghi, A, Borgnia, MJ, Sapiro, G, Subramaniam, S (2008) Molecular architecture of native HIV-1 gp120 trimers. *Nature* **455**: 109-113.

Liu, SL, Rodrigo, AG, Shankarappa, R, Learn, GH, Hsu, L, Davidov, O, Zhao, LP, Mullins, JI (1996) HIV quasispecies and resampling. *Science* **273**: 415-416.

Lole, KS, Bollinger, RC, Paranjape, RS, Gadkari, D, Kulkarni, SS, Novak, NG, Ingersoll, R, Sheppard, HW, Ray, SC (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. *J Virol* **73**: 152-160.

Loman, NJ, Misra, RV, Dallman, TJ, Constantinidou, C, Gharbia, SE, Wain, J, Pallen, MJ (2012) Performance comparison of benchtop high-throughput sequencing platforms. *Nat Biotechnol* **30**: 434-439.

Long, EM, Martin, HL, Jr., Kreiss, JK, Rainwater, SM, Lavreys, L, Jackson, DJ, Rakwar, J, Mandaliya, K, Overbaugh, J (2000) Gender differences in HIV-1 diversity at time of infection. *Nat Med* **6**: 71-75.

Lorenzi, P, Opravil, M, Hirschel, B, Chave, JP, Furrer, HJ, Sax, H, Perneger, TV, Perrin, L, Kaiser, L, Yerly, S (1999) Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. *AIDS* **13**: F17-21.

Lundgren, JD, Phillips, AN, Pedersen, C, Clumeck, N, Gatell, JM, Johnson, AM, Ledergerber, B, Vella, S, Nielsen, JO (1994) Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. *JAMA* **271**: 1088-1092.

Luo, C, Tsementzi, D, Kyrpides, N, Read, T, Konstantinidis, KT (2012) Direct comparisons of Illumina vs. Roche 454 sequencing technologies on the same microbial community DNA sample. *PLoS One* **7**: e30087.

Madani, N, Kabat, D (1998) An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. *Journal of virology* **72**: 10251-10255.

Malim, MH, Bohnlein, S, Hauber, J, Cullen, BR (1989a) Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. *Cell* **58**: 205-214.

Malim, MH, Cullen, BR (1991) HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. *Cell* **65**: 241-248.

Malim, MH, Hauber, J, Le, S-Y, Maizel, JV, Cullen, BR (1989b) The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. *Nature* **338**: 254–257.

Mansky, LM (1996) Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. *AIDS Res Hum Retroviruses* **12**: 307-314.

Mansky, LM, Temin, HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. *Journal of Virology* **69**: 5087-5094.

Marcello, A, Zoppe, M, Giacca, M (2001) Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. *IUBMB Life* **51**: 175-181.

Mardis, ER (2008) The impact of next-generation sequencing technology on genetics. *Trends Genet* **24**: 133-141.

Margulies, M, Egholm, M, Altman, WE, Attiya, S, Bader, JS, Bemben, LA, Berka, J, Braverman, MS, Chen, Y-J, Chen, Z, Dewell, SB, Du, L, Fierro, JM, Gomes, XV, Godwin, BC, He, W, Helgesen, S, Ho, CH, Irzyk, GP, Jando, SC, Alenquer, MLI, Jarvie, TP, Jirage, KB, Kim, J-B, Knight, JR, Lanza, JR, Leamon, JH, Lefkowitz, SM, Lei, M, Li, J, Lohman, KL, Lu, H, Makhijani, VB, McDade, KE, McKenna, MP, Myers, EW, Nickerson, E, Nobile, JR, Plant, R, Puc, BP, Ronan, MT, Roth, GT, Sarkis, GJ, Simons, JF, Simpson, JW, Srinivasan, M, Tartaro, KR, Tomasz, A, Vogt, KA, Volkmer, GA, Wang, SH, Wang, Y, Weiner, MP, Yu, P, Begley, RF, Rothberg, JM (2005a) Genome sequencing in microfabricated high-density picolitre reactors. *Nature* **437**: 376-380.

Margulies, M, Egholm, M, Altman, WE, Attiya, S, Bader, JS, Bemben, LA, Berka, J, Braverman, MS, Chen, YJ, Chen, Z, Dewell, SB, Du, L, Fierro, JM, Gomes, XV, Godwin, BC, He, W, Helgesen, S, Ho, CH, Irzyk, GP, Jando, SC, Alenquer, ML, Jarvie, TP, Jirage, KB, Kim, JB, Knight, JR, Lanza, JR, Leamon, JH, Lefkowitz, SM, Lei, M, Li, J, Lohman, KL, Lu, H, Makhijani, VB, McDade, KE, McKenna, MP, Myers, EW, Nickerson, E, Nobile, JR, Plant, R, Puc, BP, Ronan, MT, Roth, GT, Sarkis, GJ, Simons, JF, Simpson, JW, Srinivasan, M, Tartaro, KR, Tomasz, A, Vogt, KA, Volkmer, GA, Wang, SH, Wang, Y, Weiner, MP, Yu, P, Begley, RF, Rothberg, JM (2005b) Genome sequencing in microfabricated high-density picolitre reactors. *Nature* **437**: 376-380.

Martinez-Picado, J, Sutton, L, De Pasquale, MP, Savara, AV, D'Aquila, RT (1999) Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. *J Clin Microbiol* **37**: 2943-2951.

Mayer, KH, Hanna, GJ, Richard, T (2001) Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. *Clinical Infectious Diseases* **32**: 774-782.

McCutchan, FE (2000) Understanding the genetic diversity of HIV-1. *AIDS* **14 Suppl 3**: S31-44.

McCutchan, FE (2006) Global epidemiology of HIV. *Journal of Medical Virology* **78**: S7–S12.

McDonald, D, Vodicka, MA, Lucero, G, Svitkina, TM, Borisy, GG, Emerman, M, Hope, TJ (2002) Visualization of the intracellular behavior of HIV in living cells. *The Journal of Cell Biology* **159**: 441-452.

McGowan, JP, Shah, SS (2000) Prevention of perinatal HIV transmission during pregnancy. *Journal of Antimicrobial Chemotherapy* **46**: 657-668.

McIntyre, JA, Hopley, M, Moodley, D, Eklund, M, Gray, GE, Hall, DB, Robinson, P, Mayers, D, Martinson, NA (2009) Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. *PLoS medicine* **6**: e1000172.

Melikyan, GB (2008) Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. *Retrovirology* **5**: 111.

Melikyan, GB, Markosyan, RM, Hemmati, H, Delmedico, MK, Lambert, DM, Cohen, FS (2000) Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion. *The Journal of Cell Biology* **151**: 413-424.

Merry, C, Barry, MG, Mulcahy, F, Ryan, M, Heavey, J, Tjia, JF, Gibbons, SE, Breckenridge, AM, Back, DJ (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. *AIDS* **11**: F29-F33.

Metzker, ML (2005) Emerging technologies in DNA sequencing. *Genome Res* **15**: 1767-1776.

Metzker, ML (2009) Sequencing technologies - the next generation. *Nat Rev Genet* **11**: 31-46.

Meyerhans, A, Vartanian, JP, Wain-Hobson, S (1990) DNA recombination during PCR. *Nucleic Acids Res* **18**: 1687-1691.

Milgrew, MJ, Hammond, PA, Cumming, DRS (2004) The development of scalable sensor arrays using standard CMOS technology. *Sensors and Actuators B: Chemical* **103**: 37-42.

Miller, J, Carr, A, Smith, D, Emery, S, Law, MG, Grey, P, Cooper, DA (2000) Lipodystrophy following antiretroviral therapy of primary HIV infection. *AIDS* **14**: 2406-2407.

Miller, MD, Farnet, CM, Bushman, FD (1997) Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. *Journal of Virology* **71**: 5382-5390.

Miller, V, Phillips, A, Rottmann, C, Staszewski, S, Pauwels, R, Hertogs, K, de Bethune, MP, Kemp, SD, Bloor, S, Harrigan, PR, Larder, BA (1998) Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. *J Infect Dis* **177**: 1521-1532.

Molla, A, Korneyeva, M, Gao, Q, Vasavanonda, S, Schipper, PJ, Mo, HM, Markowitz, M, Chernyavskiy, T, Niu, P, Lyons, N, Hsu, A, Granneman, GR, Ho, DD, Boucher, CA, Leonard, JM, Norbeck, DW, Kempf, DJ (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. *Nat Med* **2**: 760-766.

Montaner, JS, Mo, T, Raboud, JM, Rae, S, Alexander, CS, Zala, C, Rouleau, D, Harrigan, PR (2000) Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. *J Infect Dis* **181**: 729-732.

Montaner, JS, Reiss, P, Cooper, D, Vella, S, Harris, M, Conway, B, Wainberg, MA, Smith, D, Robinson, P, Hall, D (1998a) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. *JAMA: the journal of the American Medical Association* **279**: 930-937.

Montaner, JS, Reiss, P, Cooper, D, Vella, S, Harris, M, Conway, B, Wainberg, MA, Smith, D, Robinson, P, Hall, D, Myers, M, Lange, JM (1998b) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. *JAMA* **279**: 930-937.

Nahmias, A, Weiss, J, Yao, X, Lee, F, Kodsi, R, Schanfield, M, Matthews, T, Bolognesi, D, Durack, D, Motulsky, A (1986) Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959. *The Lancet* **327**: 1279-1280.

Navarro, F, Landau, NR (2004) Recent insights into HIV-1 Vif. *Current Opinion in Immunology* **16**: 477-482.

Neher, RA, Leitner, T Recombination rate and selection strength in HIV intra-patient evolution. *PLoS Comput Biol* **6**: e1000660.

Nermut, MV, Hockley, DJ, Bron, P, Thomas, D, Zhang, WH, Jones, IM (1998) Further evidence for hexagonal organization of HIV gag protein in prebudding assemblies and immature virus-like particles. *J Struct Biol* **123**: 143-149.

Niedringhaus, TP, Milanova, D, Kerby, MB, Snyder, MP, Barron, AE (2011) Landscape of next-generation sequencing technologies. *Anal Chem* **83**: 4327-4341.

Nomaguchi, M, Fujita, M, Adachi, A (2008) Role of HIV-1 Vpu protein for virus spread and pathogenesis. *Microbes and Infection* **10**: 960–967.

Nowak, MA, May, RM, Anderson, RM (1990) The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. *AIDS* **4**: 1095-1103.

Ott, M, Geyer, M, Zhou, Q (2011) The Control of HIV Transcription: Keeping RNA Polymerase II on Track. *Cell Host & Microbe* **10**: 426-435.

Palmer, S, Kearney, M, Maldarelli, F, Halvas, EK, Bixby, CJ, Bazmi, H, Rock, D, Falloon, J, Davey, RT, Jr., Dewar, RL, Metcalf, JA, Hammer, S, Mellors, JW, Coffin, JM (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. *J Clin Microbiol* **43**: 406-413.

Palmisano, L, Vella, S (2011) A brief history of antiretroviral therapy of HIV infection: success and challenges. *Ann Ist Super Sanita* **47**: 44-48.

Pancera, M, Majeed, S, Ban, YE, Chen, L, Huang, CC, Kong, L, Kwon, YD, Stuckey, J, Zhou, T, Robinson, JE, Schief, WR, Sodroski, J, Wyatt, R, Kwong, PD Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. *Proc Natl Acad Sci U S A* **107**: 1166-1171.

Pandey, V, Nutter, RC, Prediger, E (2008) Applied Biosystems SOLiD™ System: Ligation‐Based Sequencing. *Next Generation Genome Sequencing: Towards Personalized Medicine*: 29-42.

Paredes, R, Lalama, CM, Ribaudo, HJ, Schackman, BR, Shikuma, C, Giguel, F, Meyer, WA, 3rd, Johnson, VA, Fiscus, SA, D'Aquila, RT, Gulick, RM, Kuritzkes, DR (2010) Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. *J Infect Dis* **201**: 662-671.

Peeters, M, Honoré, C, Huet, T, Bedjabaga, L, Ossari, S, Bussi, P, Cooper, RW, Delaporte, E (1989) Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon. *Aids* **3**: 625–630.

Pennisi, E (2010) Genomics. Semiconductors inspire new sequencing technologies. *Science* **327**: 1190.

Perrin, L, Kaiser, L, Yerly, S (2003) Travel and the spread of HIV-1 genetic variants. *Lancet Infect Dis* **3**: 22-27.

Petropoulos, CJ, Parkin, NT, Limoli, KL, Lie, YS, Wrin, T, Huang, W, Tian, H, Smith, D, Winslow, GA, Capon, DJ, Whitcomb, JM (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. *Antimicrob Agents Chemother* **44**: 920-928.

Pettit, SC, Lindquist, JN, Kaplan, AH, Swanstrom, R (2005) Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. *Retrovirology* **2**: 66.

Piketty, C, Race, E, Castiel, P, Belec, L, Peytavin, G, Si-Mohamed, A, Gonzalez-Canali, G, Weiss, L, Clavel, F, Kazatchkine, MD (1999) Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. *AIDS* **13**: F71-77.

Ping, LH, Cohen, MS, Hoffman, I, Vernazza, P, Seillier-Moiseiwitsch, F, Chakraborty, H, Kazembe, P, Zimba, D, Maida, M, Fiscus, SA, Eron, JJ, Swanstrom, R, Nelson, JA (2000) Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. *J Virol* **74**: 8946-8952.

Plantier, JC, Leoz, M, Dickerson, JE, De Oliveira, F, Cordonnier, F, Lemee, V, Damond, F, Robertson, DL, Simon, F (2009) A new human immunodeficiency virus derived from gorillas. *Nat Med* **15**: 871-872.

Poveda, E, Briz, V, Soriano, V (2005) Enfuvirtide, the first fusion inhibitor to treat HIV infection. *Aids Rev* **7**: 139–147.

Preston, BD, Poiesz, BJ, Loeb, LA (1988) Fidelity of HIV-1 reverse transcriptase. *Science* **242**: 1168-1171.

Price, DA, Goulder, PJ, Klenerman, P, Sewell, AK, Easterbrook, PJ, Troop, M, Bangham, CR, Phillips, RE (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. *Proc Natl Acad Sci U S A* **94**: 1890-1895.

Pruss, D, Reeves, R, Bushman, FD, Wolffe, AP (1994) The influence of DNA and nucleosome structure on integration events directed by HIV integrase. *Journal of Biological Chemistry* **269**: 25031-25041.

Quinn, TC (1996) Global burden of the HIV pandemic. *Lancet* **348**: 99-106.

Ratner, L, Haseltine, W, Patarca, R, Livak, KJ, Starcich, B, Josephs, SF, Doran, ER, Rafalski, JA, Whitehorn, EA, Baumeister, K (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III.

Raymond, S, Delobel, P, Mavigner, M, Cazabat, M, Encinas, S, Souyris, C, Bruel, P, Sandres-Saune, K, Marchou, B, Massip, P, Izopet, J (2010) CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. *AIDS* **24**: 2305-2312.

Razooky, BS, Weinberger, LS (2011) Mapping the architecture of the HIV-1 Tat circuit: A decision-making circuit that lacks bistability and exploits stochastic noise. *Methods* **53**: 68-77.

Rhee, SY, Gonzales, MJ, Kantor, R, Betts, BJ, Ravela, J, Shafer, RW (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. *Nucleic Acids Res* **31**: 298-303.

Richman, DD, Fischl, MA, Grieco, MH, Gottlieb, MS, Volberding, PA, Laskin, OL, Leedom, JM, Groopman, JE, Mildvan, D, Hirsch, MS, et al. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. *N Engl J Med* **317**: 192-197.

Riviere, L, Darlix, JL, Cimarelli, A (2010) Analysis of the viral elements required in the nuclear import of HIV-1 DNA. *J Virol* **84**: 729-739.

Rizzuto, CD, Wyatt, R, Hernandez-Ramos, N, Sun, Y, Kwong, PD, Hendrickson, WA, Sodroski, J (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. *Science* **280**: 1949-1953.

Robbins, GK, De Gruttola, V, Shafer, RW, Smeaton, LM, Snyder, SW, Pettinelli, C, Dubé, MP, Fischl, MA, Pollard, RB, Delapenha, R (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *New England Journal of Medicine* **349**: 2293-2303.

Roberts, JD, Bebenek, K, Kunkel, TA (1988) The accuracy of reverse transcriptase from HIV-1. *Science* **242**: 1171-1173.

Robertson, D (2003) US FDA approves new class of HIV therapeutics. *Nature Biotechnology* **21**: 470-471.

Robertson, DL, Anderson, JP, Bradac, JA, Carr, JK, Foley, B, Funkhouser, RK, Gao, F, Hahn, BH, Kalish, ML, Kuiken, C (2000a) HIV-1 nomenclature proposal. *Science* **288**: 55–55.

Robertson, DL, Anderson, JP, Bradac, JA, Carr, JK, Foley, B, Funkhouser, RK, Gao, F, Hahn, BH, Kalish, ML, Kuiken, C, Learn, GH, Leitner, T, McCutchan, F, Osmanov, S, Peeters, M, Pieniazek, D, Salminen, M, Sharp, PM, Wolinsky, S, Korber, B (2000b) HIV-1 nomenclature proposal. *Science* **288**: 55-56.

Rogel, ME, Wu, LI, Emerman, M (1995) The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. *Journal of virology* **69**: 882–888.

Rogers, MF, Thomas, PA, Starcher, ET, Noa, MC, Bush, TJ, Jaffe, HW (1987) Acquired Immunodeficiency Syndrome in Children: Report of the Centers for Disease Control National Surveillance, 1982 to 1985. *Pediatrics* **79**: 1008-1014.

Rooke, R, Tremblay, M, Soudeyns, H, DeStephano, L, Yao, XJ, Fanning, M, Montaner, JS, O'Shaughnessy, M, Gelmon, K, Tsoukas, C, et al. (1989) Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. *AIDS* **3**: 411-415.

Roques, P, Robertson, DL, Souquière, S, Damond, F, Ayouba, A, Farfara, I, Depienne, C, Nerrienet, E, Dormont, D, Brun-Vézinet, F, Simon, F, Mauclère, P (2002) Phylogenetic Analysis of 49 Newly Derived HIV-1 Group O Strains: High Viral Diversity but No Group M-like Subtype Structure. *Virology* **302**: 259-273.

Rosen, CA, Pavlakis, GN (1990a) Tat and Rev: positive regulators of HIV gene expression. *AIDS* **4**: 499-509.

Rosen, CA, Pavlakis, GN (1990b) Tat and Rev: positive regulators of HIV gene expression. *AIDS* **4**: A51.

Rothberg, JM, Hinz, W, Rearick, TM, Schultz, J, Mileski, W, Davey, M, Leamon, JH, Johnson, K, Milgrew, MJ, Edwards, M, Hoon, J, Simons, JF, Marran, D, Myers, JW, Davidson, JF, Branting, A, Nobile, JR, Puc, BP, Light, D, Clark, TA, Huber, M, Branciforte, JT, Stoner, IB, Cawley, SE, Lyons, M, Fu, Y, Homer, N, Sedova, M, Miao, X, Reed, B, Sabina, J, Feierstein, E, Schorn, M, Alanjary, M, Dimalanta, E, Dressman, D, Kasinskas, R, Sokolsky, T, Fidanza, JA, Namsaraev, E, McKernan, KJ, Williams, A, Roth, GT, Bustillo, J (2011) An integrated semiconductor device enabling non-optical genome sequencing. *Nature* **475**: 348-352.

Rowley, CF, Boutwell, CL, Lee, EJ, MacLeod, IJ, Ribaudo, HJ, Essex, M, Lockman, S Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. *AIDS Res Hum Retroviruses* **26**: 293-300.

Roy, S, Delling, U, Chen, CH, Rosen, CA, Sonenberg, N (1990) A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. *Genes Dev* **4**: 1365-1373.

Saad, JS, Miller, J, Tai, J, Kim, A, Ghanam, RH, Summers, MF (2006) Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. *Proc Natl Acad Sci U S A* **103**: 11364-11369.

Salemi, M, Strimmer, K, Hall, WW, Duffy, M, Delaporte, E, Mboup, S, Peeters, M, Vandamme, AM (2001) Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. *FASEB J* **15**: 276-278.

Sandstrom, EG, Kaplan, JC (1987) Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. *Drugs* **34**: 372-390.

Sanger, F, Nicklen, S, Coulson, AR (1977) DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* **74**: 5463-5467.

Santiago, ML, Range, F, Keele, BF, Li, Y, Bailes, E, Bibollet-Ruche, F, Fruteau, C, Noë, R, Peeters, M, Brookfield, JF (2005) Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. *Journal of virology* **79**: 12515–12527.

Sarafianos, SG, Hughes, SH, Arnold, E (2004) Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. *The International Journal of Biochemistry & Cell Biology* **36**: 1706-1715.

Sarafianos, SG, Marchand, B, Das, K, Himmel, DM, Parniak, MA, Hughes, SH, Arnold, E (2009) Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition. *Journal of Molecular Biology* **385**: 693-713.

Saravolatz, LD, Winslow, DL, Collins, G, Hodges, JS, Pettinelli, C, Stein, DS, Markowitz, N, Reves, R, Loveless, MO, Crane, L (1996) Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. *New England Journal of Medicine* **335**: 1099-1106.

Sawai, ET, Baur, A, Struble, H, Peterlin, BM, Levy, JA, Cheng-Mayer, C (1994) Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. *Proceedings of the National Academy of Sciences* **91**: 1539-1543.

Schubert, U, Ott, DE, Chertova, EN, Welker, R, Tessmer, U, Princiotta, MF, Bennink, JR, Krausslich, HG, Yewdell, JW (2000) Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. *Proc Natl Acad Sci U S A* **97**: 13057-13062.

Seelmeier, S, Schmidt, H, Turk, V, von der Helm, K (1988) Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. *Proc Natl Acad Sci U S A* **85**: 6612-6616.

Shafer, RW, Iversen, AK, Winters, MA, Aguiniga, E, Katzenstein, DA, Merigan, TC (1995) Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. *J Infect Dis* **172**: 70-78.

Shafer, RW, Merigan, TC (1995) New virologic tools for the design and analysis of clinical trials. *J Infect Dis* **171**: 1325-1328.

Shah, VB, Shi, J, Hout, DR, Oztop, I, Krishnan, L, Ahn, J, Shotwell, MS, Engelman, A, Aiken, C (2013) The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. *J Virol* **87**: 422-432.

Sharp, PM, Hahn, BH The evolution of HIV-1 and the origin of AIDS. *Philosophical Transactions of the Royal Society B: Biological Sciences* **365**: 2487-2494.

Sharp, PM, Hahn, BH (2010) The evolution of HIV-1 and the origin of AIDS. *Philosophical Transactions of the Royal Society B: Biological Sciences* **365**: 2487-2494.

Sheehy, AM, Gaddis, NC, Choi, JD, Malim, MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* **418**: 646-650.

Shi, C, Mellors, JW (1997) A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. *Antimicrob Agents Chemother* **41**: 2781-2785.

Shirasaka, T, Kavlick, MF, Ueno, T, Gao, WY, Kojima, E, Alcaide, ML, Chokekijchai, S, Roy, BM, Arnold, E, Yarchoan, R, et al. (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. *Proc Natl Acad Sci U S A* **92**: 2398-2402.

Shokralla, S, Spall, JL, Gibson, JF, Hajibabaei, M (2012) Next-generation sequencing technologies for environmental DNA research. *Mol Ecol* **21**: 1794-1805.

Simen, BB, Simons, JF, Hullsiek, KH, Novak, RM, Macarthur, RD, Baxter, JD, Huang, C, Lubeski, C, Turenchalk, GS, Braverman, MS, Desany, B, Rothberg, JM, Egholm, M, Kozal, MJ (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. *J Infect Dis* **199**: 693-701.

Simmons, A, Aluvihare, V, McMichael, A (2001) Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. *Immunity* **14**: 763-777.

Simon, F, Mauclère, P, Roques, P, Loussert-Ajaka, I, Müller-Trutwin, MC, Saragosti, S, Georges-Courbot, MC, Barré-Sinoussi, F, Brun-Vézinet, F (1998a) Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. *Nature Medicine* **4**: 1032-1037.

Simon, JHM, Gaddis, NC, Fouchier, RAM, Malim, MH (1998b) Evidence for a newly discovered cellular anti-HIV-1 phenotype. *Nature Medicine* **4**: 1397-1400.

Skowron, G, Bozzette, SA, Lim, L, Pettinelli, CB, Schaumburg, HH, Arezzo, J, Fischl, MA, Powderly, WG, Gocke, DJ, Richman, DD, Pottage, JC, Antoniskis, D, McKinley, GF, Hyslop, NE, Ray, G, Simon, G, Reed, N, LoFaro, ML, Uttamchandani, RB, Gelb, LD, Sperber, SJ, Murphy, RL, Leedom, JM, Grieco, MH, Zachary, J, Hirsch, MS, Spector, SA, Bigley, J, Soo, W, Merigan, TC (1993) Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. *Ann Intern Med* **118**: 321-330.

Sluis-Cremer, N, Arion, D, Parniak\*, MA (2000) Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). *Cellular and Molecular Life Sciences CMLS* **57**: 1408-1422.

Smyth, RP, Davenport, MP, Mak, J (2012) The origin of genetic diversity in HIV-1. *Virus Res* **169**: 415-429.

Sodroski, J, Rosen, C, Wong-Staal, F, Salahuddin, SZ, Popovic, M, Arya, S, Gallo, RC, Haseltine, WA (1985) Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. *Science* **227**: 171-173.

Staszewski, S, Morales-Ramirez, J, Tashima, KT, Rachlis, A, Skiest, D, Stanford, J, Stryker, R, Johnson, P, Labriola, DF, Farina, D (1999a) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. *New England Journal of Medicine* **341**: 1865-1873.

Staszewski, S, Morales-Ramirez, J, Tashima, KT, Rachlis, A, Skiest, D, Stanford, J, Stryker, R, Johnson, P, Labriola, DF, Farina, D, Manion, DJ, Ruiz, NM (1999b) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. *N Engl J Med* **341**: 1865-1873.

Strebel, K, Klimkait, T, Martin, MA (1988) A novel gene of HIV-1, vpu, and its 16-kilodalton product. *Science* **241**: 1221-1223.

Struck, D, Wallis, CL, Denisov, G, Lambert, C, Servais, JY, Viana, RV, Letsoalo, E, Bronze, M, Aitken, SC, Schuurman, R, Stevens, W, Schmit, JC, Rinke de Wit, T, Perez Bercoff, D (2012) Automated sequence analysis and editing software for HIV drug resistance testing. *J Clin Virol* **54**: 30-35.

Stuhlmann, H, Berg, P (1992) Homologous recombination of copackaged retrovirus RNAs during reverse transcription. *J Virol* **66**: 2378-2388.

Stuyver, L, Wyseur, A, Rombout, A, Louwagie, J, Scarcez, T, Verhofstede, C, Rimland, D, Schinazi, RF, Rossau, R (1997) Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. *Antimicrob Agents Chemother* **41**: 284-291.

Tan, K, Liu, J-h, Wang, J-h, Shen, S, Lu, M (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. *Proceedings of the National Academy of Sciences* **94**: 12303-12308.

Taylor, BS, Sobieszczyk, ME, McCutchan, FE, Hammer, SM (2008) The Challenge of HIV-1 Subtype Diversity. *New England Journal of Medicine* **358**: 1590-1602.

Tersmette, M, Gruters, RA, Wolf, Fd, Goede, REd, Lange, JM, Schellekens, PT, Goudsmit, J, Huisman, HG, Miedema, F (1989) Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. *Journal of Virology* **63**: 2118-2125.

Thompson, SR, Sarnow, P (2000) Regulation of host cell translation by viruses and effects on cell function. *Curr Opin Microbiol* **3**: 366-370.

Tisdale, M, Kemp, SD, Parry, NR, Larder, BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. *Proc Natl Acad Sci U S A* **90**: 5653-5656.

Tovanabutra, S, Robison, V, Wongtrakul, J, Sennum, S, Suriyanon, V, Kingkeow, D, Kawichai, S, Tanan, P, Duerr, A, Nelson, KE (2002) Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. *J Acquir Immune Defic Syndr* **29**: 275-283.

Tsiodras, S, Mantzoros, C, Hammer, S, Samore, M (2000) Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. *Arch Intern Med* **160**: 2050-2056.

UNAIDS (2012) Global Report 2012: UNAIDS Report on the Global AIDS Epidemic. ebookpartnership. com.

Vacca, JP, Dorsey, BD, Schleif, WA, Levin, RB, McDaniel, SL, Darke, PL, Zugay, J, Quintero, JC, Blahy, OM, Roth, E (1994) L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. *Proceedings of the National Academy of Sciences* **91**: 4096-4100.

Vacca, JP, Guare, JP, deSolms, SJ, Sanders, WM, Giuliani, EA, Young, SD, Darke, PL, Zugay, J, Sigal, IS, Schleif, WA, et al. (1991) L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. *J Med Chem* **34**: 1225-1228.

Vallari, A, Holzmayer, V, Harris, B, Yamaguchi, J, Ngansop, C, Makamche, F, Mbanya, D, Kaptué, L, Ndembi, N, Gürtler, L, Devare, S, Brennan, CA (2011) Confirmation of Putative HIV-1 Group P in Cameroon. *Journal of Virology* **85**: 1403-1407.

van Leeuwen, R, Katlama, C, Kitchen, V, Boucher, CA, Tubiana, R, McBride, M, Ingrand, D, Weber, J, Hill, A, McDade, H, et al. (1995) Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. *J Infect Dis* **171**: 1166-1171.

Van Vaerenbergh, K (2001) Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. *Verhandelingen - Koninklijke Academie voor Geneeskunde van België* **63**: 447-473.

Van Vaerenbergh, K, Van Laethem, K, Van Wijngaerden, E, Schmit, JC, Schneider, F, Ruiz, L, Clotet, B, Verhofstede, C, Van Wanzeele, F, Muyldermans, G, Simons, P, Stuyver, L, Hermans, P, Evans, C, De Clercq, E, Desmyter, J, Vandamme, AM (2000) Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy. *AIDS Res Hum Retroviruses* **16**: 529-537.

VANDEN HAESEVELDE, MM, Peeters, M, JANNES, G, JANSSENS, W, VAN DER GROEN, G, SHARP, PM, SAMAN, E (1996) Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee. *Virology* **221**: 346–350.

Vella, S, Schwartlander, B, Sow, SP, Eholie, SP, Murphy, RL (2012) The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. *AIDS* **26**: 1231-1241.

Volberding, PA, Lagakos, SW, Grimes, JM, Stein, DS, Rooney, J, Meng, TC, Fischl, MA, Collier, AC, Phair, JP, Hirsch, MS, et al. (1995) A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. *N Engl J Med* **333**: 401-407.

Volberding, PA, Lagakos, SW, Koch, MA, Pettinelli, C, Myers, MW, Booth, DK, Balfour, HH, Jr., Reichman, RC, Bartlett, JA, Hirsch, MS, et al. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. *N Engl J Med* **322**: 941-949.

von Schwedler, U, Song, J, Aiken, C, Trono, D (1993) Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. *Journal of virology* **67**: 4945-4955.

Wain-Hobson, S, Sonigo, P, Danos, O, Cole, S, Alizon, M (1985) Nucleotide sequence of the AIDS virus, LAV. *Cell* **40**: 9–17.

Wang, C, Mitsuya, Y, Gharizadeh, B, Ronaghi, M, Shafer, RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. *Genome Res* **17**: 1195-1201.

Wang, C-T, Barklis, E (1993) Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. *Journal of virology* **67**: 4264–4273.

Wang, R-R, Yang, L-M, Wang, Y-H, Pang, W, Tam, S-C, Tien, P, Zheng, Y-T (2009) Sifuvirtide, a potent HIV fusion inhibitor peptide. *Biochemical and Biophysical Research Communications* **382**: 540-544.

Ward, JW, Grindon, AJ, Feorino, PM, Schable, C, Parvin, M, Allen, JR (1986) Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. *JAMA* **256**: 357-361.

Wasi, C, Herring, B, Raktham, S, Vanichseni, S, Mastro, TD, Young, NL, Rubsamen-Waigmann, H, von Briesen, H, Kalish, ML, Luo, CC, et al. (1995) Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. *AIDS* **9**: 843-849.

Weinberg, JL, Kovarik, CL (2010) The WHO Clinical Staging System for HIV/AIDS. *Virtual Mentor* **12**: 202-206.

Westby, M, van der Ryst, E (2005) CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. *Antivir Chem Chemother* **16**: 339-354.

Wiegers, K, Rutter, G, Kottler, H, Tessmer, U, Hohenberg, H, Krausslich, HG (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. *J Virol* **72**: 2846-2854.

Wild, C, Greenwell, T, Matthews, T (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. *AIDS research and human retroviruses* **9**: 1051-1053.

Willey, RL, Maldarelli, F, Martin, MA, Strebel, K (1992) Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. *Journal of Virology* **66**: 7193-7200.

Wofsy, C, Hauer, L, Michaelis, B, Cohen, J, Padian, N, Evans, L, Levy, J (1986) Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. *The Lancet* **327**: 527–529.

Woods, CK, Brumme, CJ, Liu, TF, Chui, CK, Chu, AL, Wynhoven, B, Hall, TA, Trevino, C, Shafer, RW, Harrigan, PR (2012) Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. *J Clin Microbiol* **50**: 1936-1942.

Worobey, M, Gemmel, M, Teuwen, DE, Haselkorn, T, Kunstman, K, Bunce, M, Muyembe, JJ, Kabongo, JM, Kalengayi, RM, Van Marck, E, Gilbert, MT, Wolinsky, SM (2008) Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. *Nature* **455**: 661-664.

Wu, L, Gerard, NP, Wyatt, R, Choe, H, Parolin, C, Ruffing, N, Borsetti, A, Cardoso, AA, Desjardin, E, Newman, W, Gerard, C, Sodroski, J (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. *Nature* **384**: 179-183.

Wu, L, LaRosa, G, Kassam, N, Gordon, CJ, Heath, H, Ruffing, N, Chen, H, Humblias, J, Samson, M, Parmentier, M, Moore, JP, Mackay, CR (1997) Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding. *The Journal of Experimental Medicine* **186**: 1373-1381.

Yang, YL, Wang, G, Dorman, K, Kaplan, AH (1996) Long polymerase chain reaction amplification of heterogeneous HIV type 1 templates produces recombination at a relatively high frequency. *AIDS Res Hum Retroviruses* **12**: 303-306.

Zaidi, J, Grapsa, E, Tanser, F, Newell, M-L, Bärnighausen, T Dramatic increases in HIV prevalence after scale-up of antiretroviral treatment: a longitudinal population-based HIV surveillance study in rural kwazulu-natal. *AIDS* **27**: 000-000.

Zhang, Y, Qian, H, Love, Z, Barklis, E (1998) Analysis of the Assembly Function of the Human Immunodeficiency Virus Type 1 Gag Protein Nucleocapsid Domain. *Journal of Virology* **72**: 1782-1789.

Zhou, W, Resh, MD (1996) Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. *J Virol* **70**: 8540-8548.

Zhu, T, Korber, BT, Nahmias, AJ, Hooper, E, Sharp, PM, Ho, DD (1998) An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. *Nature* **391**: 594-597.

Ziegler, J, Johnson, R, Cooper, D, Gold, J (1985) Postnatal transmission of AIDS-associated retrovirus from mother to infant. *The Lancet* **325**: 896–898.

Zolopa, AR, Shafer, RW, Warford, A, Montoya, JG, Hsu, P, Katzenstein, D, Merigan, TC, Efron, B (1999) HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. *Ann Intern Med* **131**: 813-821.